HK1083510A1 - Antibodies against pd-1 and uses thereof - Google Patents

Antibodies against pd-1 and uses thereof

Info

Publication number: HK1083510A1
Authority: HK; Hong Kong
Prior art keywords: antibodies against; tcr; allergies; agonists; antagonists
Prior art date: 2002-12-23

Application number

HK06103433.3A

Other languages

English (en)

Inventor

Mary Collins

Clive Wood

Beatriz Carreno

Viia Valge-Archer

Deborah Luxenberg

Jason Jussif

Caroline Russell

Laura L Carter

Frances Bennett

John Andrews

Original Assignee

Wyeth Llc

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-23

Filing date

2006-03-17

Publication date

2006-07-07

2006-03-17 Application filed by Wyeth Llc, Medimmune Ltd filed Critical Wyeth Llc

2006-07-07 Publication of HK1083510A1 publication Critical patent/HK1083510A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HK06103433.3A 2002-12-23 2006-03-17 Antibodies against pd-1 and uses thereof HK1083510A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43535402P	2002-12-23	2002-12-23
PCT/IB2003/006304 WO2004056875A1 (en)	2002-12-23	2003-12-22	Antibodies against pd-1 and uses therefor

Publications (1)

Publication Number	Publication Date
HK1083510A1 true HK1083510A1 (en)	2006-07-07

Family

ID=32682224

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK06103433.3A HK1083510A1 (en)	2002-12-23	2006-03-17	Antibodies against pd-1 and uses thereof

Country Status (14)

Country	Link
US (4)	US7521051B2 (zh)
EP (1)	EP1576014B1 (zh)
JP (2)	JP4511943B2 (zh)
CN (2)	CN101899114A (zh)
AT (1)	ATE514713T1 (zh)
AU (2)	AU2003288675B2 (zh)
BR (1)	BR0316880A (zh)
CA (1)	CA2508660C (zh)
ES (1)	ES2367430T3 (zh)
HK (1)	HK1083510A1 (zh)
IL (1)	IL169152A (zh)
MX (1)	MXPA05006828A (zh)
NO (1)	NO336442B1 (zh)
WO (1)	WO2004056875A1 (zh)

Families Citing this family (1218)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
HUE065675T2 (hu)	2002-07-03	2024-06-28	Ono Pharmaceutical Co	PD-L1 elleni antitesteket tartalmazó immunpotenciáló készítmények
AU2003288675B2 (en) *	2002-12-23	2010-07-22	Medimmune Limited	Antibodies against PD-1 and uses therefor
WO2005091716A2 (en) *	2004-03-26	2005-10-06	Quark Biotech, Inc.	Annexin ii and uses thereof
FI3428191T3 (fi) *	2004-10-06	2025-01-21	Mayo Found Medical Education & Res	B7-h1 ja pd-1 munuaissolukarsinooman hoidossa
EP2418278A3 (en)	2005-05-09	2012-07-04	Ono Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2012204032B2 (en) *	2005-06-08	2014-01-16	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
KR101804078B1 (ko) *	2005-06-08	2017-12-01	다나-파버 캔서 인스티튜트 인크.	예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
EP2982379A1 (en)	2005-07-01	2016-02-10	E. R. Squibb & Sons, L.L.C.	Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
SI2347775T1 (sl)	2005-12-13	2020-10-30	President And Fellows Of Harvard College	Ogrodja za celično transplantacijo
WO2007100098A1 (ja)	2006-03-03	2007-09-07	Kyoto University	細胞表面機能分子の細胞外領域多量体
PL2772535T3 (pl)	2006-05-31	2022-09-05	Children's Medical Center Corporation	Mezenchymalne komórki macierzyste ABC5 dodatnie jako immunomodulatory
EP2079760B1 (en)	2006-12-27	2016-04-27	Emory University	Compositions and methods for the treatment of infections
EP2155248B1 (en)	2007-04-12	2015-06-10	The Brigham and Women's Hospital, Inc.	Targeting abcb5 for cancer therapy
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
AU2014201367B2 (en) *	2007-06-18	2016-01-28	Merck Sharp & Dohme B.V.	Antibodies to human programmed death receptor pd-1
PT2170959E (pt) *	2007-06-18	2014-01-07	Merck Sharp & Dohme	Anticorpos para o receptor humano de morte programada pd-1
AU2008287063B2 (en) *	2007-08-09	2013-10-24	Genzyme Corporation	Method of treating autoimmune disease with mesenchymal stem cells
WO2009033009A2 (en)	2007-09-05	2009-03-12	Inotek Pharmaceuticals Corporation	Antibodies against flagellin and uses thereof
US10328133B2 (en)	2008-02-13	2019-06-25	President And Fellows Of Harvard College	Continuous cell programming devices
WO2009114335A2 (en) *	2008-03-12	2009-09-17	Merck & Co., Inc.	Pd-1 binding proteins
DK2853269T3 (da)	2008-05-19	2019-08-05	Advaxis Inc	Dobbelt indgivelsessystem til heterologe antigener, der omfatter en rekombinant Listeria-stamme svækket ved mutation af dal/dat og deletion af ActA, der omfatter et nukleinsyremolekyle, der koder for et listeriolysin O-prostataspecifikt antigenfusionsprotein
US9650639B2 (en)	2008-05-19	2017-05-16	Advaxis, Inc.	Dual delivery system for heterologous antigens
US9017660B2 (en)	2009-11-11	2015-04-28	Advaxis, Inc.	Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
EP2328920A2 (en) *	2008-08-25	2011-06-08	Amplimmune, Inc.	Targeted costimulatory polypeptides and methods of use to treat cancer
EA201500417A1 (ru)	2008-08-25	2015-11-30	Эмплиммьюн, Инк.	Композиции антагонистов pd-1 и способы применения
AU2009290544B2 (en) *	2008-09-12	2015-07-16	Oxford University Innovation Limited	PD-1 specific antibodies and uses thereof
AU2009290543B2 (en) *	2008-09-12	2015-09-03	Oxford University Innovation Limited	PD-1 specific antibodies and uses thereof
SI2342226T1 (sl) *	2008-09-26	2016-11-30	Dana-Farber Cancer Institute Inc.	Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
KR20190064664A (ko)	2008-10-02	2019-06-10	압테보 리서치 앤드 디벨롭먼트 엘엘씨	Ｃｄ86 길항제 다중-표적 결합 단백질
PT3130923T (pt)	2008-11-14	2020-06-17	Brigham & Womens Hospital Inc	Métodos terapêuticos relacionados com células estaminais
US11542328B2 (en)	2008-11-14	2023-01-03	The Brigham And Women's Hospital, Inc.	Therapeutic and diagnostic methods relating to cancer stem cells
CA2744449C (en)	2008-11-28	2019-01-29	Emory University	Methods for the treatment of infections and tumors
PT2376535T (pt)	2008-12-09	2017-06-23	Hoffmann La Roche	Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t
JP5844159B2 (ja) *	2009-02-09	2016-01-13	ユニヴェルシテデクス−マルセイユＵｎｉｖｅｒｓｉｔｅＤ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ	Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US20100239583A1 (en) *	2009-03-04	2010-09-23	Inotek Pharmaceuticals Corporation	Antibodies against flagellin and uses thereof
MY160203A (en)	2009-03-30	2017-02-28	Eisai R&D Man Co Ltd	Liposome composition
EP3375791A1 (en)	2009-09-30	2018-09-19	Memorial Sloan Kettering Cancer Center	Combination immunotherapy for the treatment of cancer
US10016617B2 (en)	2009-11-11	2018-07-10	The Trustees Of The University Of Pennsylvania	Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US20130202623A1 (en) *	2010-02-16	2013-08-08	Nicolas Chomont	Pd-1 modulation and uses thereof for modulating hiv replication
TW201134488A (en) *	2010-03-11	2011-10-16	Ucb Pharma Sa	PD-1 antibodies
WO2011110604A1 (en)	2010-03-11	2011-09-15	Ucb Pharma, S.A.	Pd-1 antibody
US10745467B2 (en)	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
AU2011230537C1 (en)	2010-03-26	2018-08-02	Trustees Of Dartmouth College	Vista regulatory T cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en)	2012-06-22	2015-08-20	Randolph J. Noelle	VISTA Antagonist and Methods of Use
JP2013532153A (ja)	2010-06-18	2013-08-15	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US9783578B2 (en)	2010-06-25	2017-10-10	Aurigene Discovery Technologies Limited	Immunosuppression modulating compounds
US8907053B2 (en)	2010-06-25	2014-12-09	Aurigene Discovery Technologies Limited	Immunosuppression modulating compounds
WO2012047583A2 (en) *	2010-09-27	2012-04-12	Janssen Biotech, Inc.	Antibodies binding human collagen ii
US8906649B2 (en)	2010-09-27	2014-12-09	Janssen Biotech, Inc.	Antibodies binding human collagen II
CN107412756A (zh)	2010-10-01	2017-12-01	宾夕法尼亚大学理事会	李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
PT2624873T (pt)	2010-10-06	2020-03-04	Harvard College	Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
WO2012125551A1 (en)	2011-03-11	2012-09-20	Advaxis	Listeria-based adjuvants
EP3398612A1 (en)	2011-03-31	2018-11-07	Merck Sharp & Dohme Corp.	Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2012145469A1 (en)	2011-04-19	2012-10-26	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human monoclonal antibodies specific for glypican-3 and use thereof
RS57324B1 (sr)	2011-04-20	2018-08-31	Medimmune Llc	Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
CN103732238A (zh)	2011-06-08	2014-04-16	奥瑞基尼探索技术有限公司	用于免疫调节的治疗性化合物
EP2726494B1 (en)	2011-06-28	2017-01-04	Whitehead Institute For Biomedical Research	Using sortases to install click chemistry handles for protein ligation
HUE052198T2 (hu)	2011-07-21	2021-04-28	Sumitomo Dainippon Pharma Oncology Inc	Heterociklusos protein kináz inhibitorok
EP2742953B1 (en) *	2011-08-11	2021-09-22	ONO Pharmaceutical Co., Ltd.	Therapeutic agent for autoimmune diseases comprising pd-1 agonist
EP4079319A1 (en) *	2011-10-17	2022-10-26	IO Biotech ApS	Pd-l1 based immunotherapy
EP2822957A1 (en)	2012-03-07	2015-01-14	Aurigene Discovery Technologies Limited	Peptidomimetic compounds as immunomodulators
EP2825195A4 (en)	2012-03-12	2015-10-07	Advaxis Inc	INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
KR20140142736A (ko)	2012-03-29	2014-12-12	오리진 디스커버리 테크놀로지스 리미티드	인간의 pd1의 bc 루프로부터의 면역조절 사이클릭 화합물
CA2869748C (en)	2012-04-12	2017-10-24	Yale University	Vehicles for controlled delivery of different pharmaceutical agents
LT2838515T (lt)	2012-04-16	2020-03-10	President And Fellows Of Harvard College	Mezoporinės silico dioksido kompozicijos, skirtos imuninio atsako moduliavimui
KR102193343B1 (ko)	2012-05-15	2020-12-22	브리스톨-마이어스 스큅 컴퍼니	Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
CN104736168B (zh) *	2012-05-31	2018-09-21	索伦托治疗有限公司	与pd-l1结合的抗原结合蛋白
SMT202000673T1 (it)	2012-06-13	2021-01-05	Incyte Holdings Corp	Composti triciclici sostituiti come inibitori di fgfr
US9890215B2 (en)	2012-06-22	2018-02-13	King's College London	Vista modulators for diagnosis and treatment of cancer
TWI705073B (zh)	2012-06-22	2020-09-21	達特茅斯學院基金會	新穎之vista-ig構築體及vista-ig用於治療自體免疫、過敏及發炎病症之用途
CN103566377A (zh)	2012-07-18	2014-02-12	上海博笛生物科技有限公司	癌症的靶向免疫治疗
KR20210008155A (ko)	2012-08-30	2021-01-20	암젠 인크	단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
AU2013312211B2 (en)	2012-09-07	2018-03-29	King's College London	VISTA modulators for diagnosis and treatment of cancer
WO2014122271A1 (en)	2013-02-07	2014-08-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas
UY35340A (es)	2013-02-20	2014-09-30	Novartis Ag	Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
HUE046961T2 (hu)	2013-02-20	2020-04-28	Univ Pennsylvania	Rák kezelése humanizált EGFRVIII elleni kiméra antigénreceptor alkalmazásával
LT2964638T (lt)	2013-03-06	2017-12-27	Astrazeneca Ab	Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
WO2014165082A2 (en) *	2013-03-13	2014-10-09	Medimmune, Llc	Antibodies and methods of detection
US9308236B2 (en)	2013-03-15	2016-04-12	Bristol-Myers Squibb Company	Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI654206B (zh)	2013-03-16	2019-03-21	諾華公司	使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
WO2014165422A1 (en)	2013-04-02	2014-10-09	Merck Sharp & Dohme Corp.	Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2014168941A1 (en)	2013-04-09	2014-10-16	Lixte Biotechnology, Inc.	Formulations of oxabicycloheptanes and oxabicycloheptenes
AU2014254019B2 (en)	2013-04-18	2018-09-27	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
SG11201508328PA (en)	2013-04-19	2015-11-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
MX2015015037A (es)	2013-05-02	2016-07-08	Anaptysbio Inc	Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
US10260038B2 (en)	2013-05-10	2019-04-16	Whitehead Institute For Biomedical Research	Protein modification of living cells using sortase
ES2901383T3 (es)	2013-05-10	2022-03-22	Whitehead Inst Biomedical Res	Producción in vitro de glóbulos rojos con proteínas marcables con sortasa
WO2014194293A1 (en)	2013-05-30	2014-12-04	Amplimmune, Inc.	Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CN111423511B (zh) *	2013-05-31	2024-02-23	索伦托药业有限公司	与pd-1结合的抗原结合蛋白
JP2016528879A (ja)	2013-06-17	2016-09-23	アルモ・バイオサイエンシーズ・インコーポレイテッド	タンパク質の同一性および安定性を評価する方法
TWI646230B (zh)	2013-08-05	2019-01-01	扭轉生物科技有限公司	重新合成之基因庫
EP3995507B1 (en)	2013-08-08	2023-10-04	Cytune Pharma	Il-15 and il-15ralpha sushi domain based on modulokines
LT3030262T (lt)	2013-08-08	2020-03-10	Cytune Pharma	Kombinuota farmacinė kompozicija
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
JP6586087B2 (ja)	2013-08-20	2019-10-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
CN105658232A (zh)	2013-08-30	2016-06-08	阿尔莫生物科技股份有限公司	使用白细胞介素-10治疗疾病和病症的方法
EP3385257A1 (en)	2013-09-06	2018-10-10	Aurigene Discovery Technologies Limited	1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
EP3041827B1 (en)	2013-09-06	2018-04-18	Aurigene Discovery Technologies Limited	1,2,4-oxadiazole derivatives as immunomodulators
CA2922982A1 (en)	2013-09-06	2015-03-12	Aurigene Discovery Technologies Limited	Cyclic peptidomimetic compounds as immunomodulators
US10077305B2 (en) *	2013-09-10	2018-09-18	Medimmune Limited	Antibodies against PD-1 and uses thereof
SMT202300039T1 (it)	2013-09-13	2023-03-17	Beigene Switzerland Gmbh	Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
CN104558177B (zh) *	2013-10-25	2020-02-18	苏州思坦维生物技术股份有限公司	拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
WO2015066413A1 (en)	2013-11-01	2015-05-07	Novartis Ag	Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
EP3062779B1 (en)	2013-11-01	2024-06-12	Yale University	Modular particles for immunotherapy
EP3068425B1 (en)	2013-11-11	2021-01-27	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
WO2015073746A2 (en)	2013-11-13	2015-05-21	Whitehead Institute For Biomedical Research	18f labeling of proteins using sortases
EP3068435A1 (en)	2013-11-13	2016-09-21	Novartis AG	Mtor inhibitors for enhancing the immune response
WO2015088930A1 (en)	2013-12-10	2015-06-18	Merck Sharp & Dohme Corp.	Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
WO2015085847A1 (zh)	2013-12-12	2015-06-18	上海恒瑞医药有限公司	Pd-1抗体、其抗原结合片段及其医药用途
WO2015094992A1 (en)	2013-12-17	2015-06-25	Merck Sharp & Dohme Corp.	Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
JP6779785B2 (ja)	2013-12-19	2020-11-04	ノバルティスアーゲー	ヒトメソテリンキメラ抗原受容体およびその使用
US11014987B2 (en)	2013-12-24	2021-05-25	Janssen Pharmaceutics Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG10201912797XA (en)	2013-12-24	2020-02-27	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments
CN114671954A (zh)	2014-01-10	2022-06-28	博笛生物科技有限公司	靶向her2阳性肿瘤的化合物和组合物
JO3517B1 (ar)	2014-01-17	2020-07-05	Novartis Ag	ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
TWI681969B (zh)	2014-01-23	2020-01-11	美商再生元醫藥公司	針對ｐｄ-１的人類抗體
TWI680138B (zh)	2014-01-23	2019-12-21	美商再生元醫藥公司	抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) *	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3971209A1 (en)	2014-02-04	2022-03-23	Pfizer Inc.	Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
WO2015119923A1 (en)	2014-02-04	2015-08-13	Pfizer Inc.	Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer
JP2017508785A (ja)	2014-02-04	2017-03-30	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
KR20160119867A (ko)	2014-03-05	2016-10-14	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
WO2015138920A1 (en)	2014-03-14	2015-09-17	Novartis Ag	Antibody molecules to lag-3 and uses thereof
WO2015142675A2 (en)	2014-03-15	2015-09-24	Novartis Ag	Treatment of cancer using chimeric antigen receptor
PL3122745T3 (pl)	2014-03-24	2019-08-30	Novartis Ag	Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych
WO2015157252A1 (en)	2014-04-07	2015-10-15	BROGDON, Jennifer	Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2015168379A2 (en) *	2014-04-30	2015-11-05	President And Fellows Of Harvard College	Combination vaccine devices and methods of killing cancer cells
US20170158776A1 (en)	2014-05-15	2017-06-08	Bristol-Myers Squibb Company	Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MA39906A (fr)	2014-05-23	2017-03-01	Eisai R&D Man Co Ltd	Polythérapies pour le traitement du cancer
JP2017516779A (ja)	2014-05-28	2017-06-22	アイデニクス・ファーマシューティカルズ・エルエルシー	癌治療のためのヌクレオシド誘導体
NZ764826A (en)	2014-05-28	2024-09-27	Memorial Sloan Kettering Cancer Center	Anti-gitr antibodies and methods of use thereof
WO2015187295A2 (en)	2014-06-02	2015-12-10	Armo Biosciences, Inc.	Methods of lowering serum cholesterol
PT3151921T (pt)	2014-06-06	2019-11-21	Bristol Myers Squibb Co	Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
MX2016016310A (es)	2014-06-11	2017-10-20	A Green Kathy	Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
US10092645B2 (en)	2014-06-17	2018-10-09	Medimmune Limited	Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3683238A1 (en) *	2014-06-19	2020-07-22	Regeneron Pharmaceuticals, Inc.	Non-human animals having a humanized programmed cell death 1 gene
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016000619A1 (en)	2014-07-03	2016-01-07	Beigene, Ltd.	Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
CN105440135A (zh)	2014-09-01	2016-03-30	博笛生物科技有限公司	用于治疗肿瘤的抗-pd-l1结合物
CN107074958A (zh)	2014-07-09	2017-08-18	博笛生物科技有限公司	用于治疗肿瘤的抗‑pd‑l1组合
PL3169341T3 (pl)	2014-07-16	2019-12-31	Transgene Sa	Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
AU2015289081B2 (en)	2014-07-16	2020-02-06	Transgene Sa	Combination of oncolytic virus with immune checkpoint modulators
US9907849B2 (en)	2014-07-18	2018-03-06	Advaxis, Inc.	Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
EP3722316A1 (en)	2014-07-21	2020-10-14	Novartis AG	Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
JP2017528433A (ja)	2014-07-21	2017-09-28	ノバルティスアーゲー	低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014688A2 (en)	2014-07-22	2016-01-28	Junzhuan Qiu	Anti-pd-1 antibodies
CN105330740B (zh) *	2014-07-30	2018-08-17	珠海市丽珠单抗生物技术有限公司	抗pd-1抗体及其应用
US20170209492A1 (en)	2014-07-31	2017-07-27	Novartis Ag	Subset-optimized chimeric antigen receptor-containing t-cells
US9982052B2 (en)	2014-08-05	2018-05-29	MabQuest, SA	Immunological reagents
JP6909153B2 (ja)	2014-08-05	2021-07-28	アポロミクスインコーポレイテッド	抗ｐｄ−ｌ１抗体
JP6629321B2 (ja) *	2014-08-05	2020-01-15	マブクエストエスエーＭａｂＱｕｅｓｔＳＡ	免疫学的試薬
US10160726B2 (en)	2014-08-06	2018-12-25	Novartis Ag	Quinolone derivatives as antibacterials
AU2015301460B2 (en)	2014-08-14	2021-04-08	Novartis Ag	Treatment of cancer using GFR alpha-4 chimeric antigen receptor
JP7084138B2 (ja)	2014-08-19	2022-06-14	ノバルティスアーゲー	癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ）
WO2016032927A1 (en)	2014-08-25	2016-03-03	Pfizer Inc.	Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US9535074B2 (en)	2014-09-08	2017-01-03	Merck Sharp & Dohme Corp.	Immunoassay for soluble PD-L1
JP6681905B2 (ja)	2014-09-13	2020-04-15	ノバルティスアーゲー	Ａｌｋ阻害剤の併用療法
EP3193931B1 (en) *	2014-09-16	2020-08-05	Innate Pharma	Neutralization of inhibitory pathways in lymphocytes
PL3194443T3 (pl)	2014-09-17	2022-01-31	Novartis Ag	Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
EP3662903A3 (en)	2014-10-03	2020-10-14	Novartis AG	Combination therapies
US10053683B2 (en)	2014-10-03	2018-08-21	Whitehead Institute For Biomedical Research	Intercellular labeling of ligand-receptor interactions
EP3204777B1 (en)	2014-10-08	2024-06-12	Novartis AG	Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964155A1 (en)	2014-10-10	2016-04-14	Idera Pharmaceuticals, Inc.	Treatment of cancer using tlr9 agonist with checkpoint inhibitors
US9732119B2 (en)	2014-10-10	2017-08-15	Bristol-Myers Squibb Company	Immunomodulators
CR20170143A (es)	2014-10-14	2017-06-19	Dana Farber Cancer Inst Inc	Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CN107001438A (zh)	2014-10-14	2017-08-01	阿尔莫生物科技股份有限公司	白细胞介素‑15组合物及其用途
WO2016064817A1 (en)	2014-10-22	2016-04-28	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
GB201419084D0 (en) *	2014-10-27	2014-12-10	Agency Science Tech & Res	Anti-PD-1 antibodies
JP6920989B2 (ja)	2014-10-29	2021-08-18	ファイヴプライムセラピューティクスインク	がんのための併用療法
JP7305300B2 (ja)	2014-11-05	2023-07-10	ザリージェンツオブザユニバーシティオブカリフォルニア	併用免疫療法
US10822414B2 (en)	2014-11-11	2020-11-03	Sutro Biopharma, Inc.	Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
US20170313775A1 (en)	2014-11-13	2017-11-02	The Johns Hopkins University	Checkpoint Blockade and Microsatellite Instability
MA40913A (fr)	2014-11-14	2017-09-20	Novartis Ag	Conjugués anticorps-médicament
US9856292B2 (en)	2014-11-14	2018-01-02	Bristol-Myers Squibb Company	Immunomodulators
US20160169869A1 (en)	2014-11-20	2016-06-16	Promega Corporation	Systems and methods for assessing modulators of immune checkpoints
WO2016090034A2 (en)	2014-12-03	2016-06-09	Novartis Ag	Methods for b cell preconditioning in car therapy
WO2016090070A1 (en)	2014-12-04	2016-06-09	Bristol-Myers Squibb Company	Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
CN107405398A (zh)	2014-12-05	2017-11-28	伊穆奈克斯特股份有限公司	鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
WO2016089797A1 (en)	2014-12-05	2016-06-09	Merck Sharp & Dohme Corp.	Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10508108B2 (en)	2014-12-05	2019-12-17	Merck Sharp & Dohme Corp.	Tricyclic compounds as inhibitors of mutant IDH enzymes
US10086000B2 (en)	2014-12-05	2018-10-02	Merck Sharp & Dohme Corp.	Tricyclic compounds as inhibitors of mutant IDH enzymes
BR112017012222A2 (pt)	2014-12-09	2018-01-30	Merck Sharp & Dohme	métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
BR112017011982A2 (pt)	2014-12-09	2018-01-16	Regeneron Pharma	roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.
TWI595006B (zh)	2014-12-09	2017-08-11	禮納特神經系統科學公司	抗ｐｄ－１抗體類和使用彼等之方法
ME03546B (me)	2014-12-16	2020-07-20	Novartis Ag	Jedinjenja izoksazol hidroksamske kiseline kао inhibiтori lpxc
AU2015362687B2 (en)	2014-12-18	2021-12-09	Amgen Inc.	Stable frozen herpes simplex virus formulation
US9861680B2 (en)	2014-12-18	2018-01-09	Bristol-Myers Squibb Company	Immunomodulators
US9944678B2 (en)	2014-12-19	2018-04-17	Bristol-Myers Squibb Company	Immunomodulators
US20170340733A1 (en)	2014-12-19	2017-11-30	Novartis Ag	Combination therapies
US10975442B2 (en)	2014-12-19	2021-04-13	Massachusetts Institute Of Technology	Molecular biomarkers for cancer immunotherapy
NZ771297A (en)	2014-12-31	2024-11-29	Checkmate Pharmaceuticals Inc	Combination tumor immunotherapy
CN107428818A (zh)	2015-01-29	2017-12-01	密西根州立大学校董会	隐藏多肽及其用途
US11786457B2 (en)	2015-01-30	2023-10-17	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US10618970B2 (en)	2015-02-03	2020-04-14	Armo Biosciences, Inc.	Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160222060A1 (en)	2015-02-04	2016-08-04	Bristol-Myers Squibb Company	Immunomodulators
UA121669C2 (uk)	2015-02-20	2020-07-10	Інсайт Корпорейшн	Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
NZ733854A (en)	2015-02-26	2022-07-01	Merck Patent Gmbh	Pd-1 / pd-l1 inhibitors for the treatment of cancer
CN107810013B (zh)	2015-03-04	2021-04-02	默沙东公司	用于治疗癌症的pd-1拮抗剂和艾立布林的组合
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
CA2978679A1 (en)	2015-03-06	2016-09-15	Beyondspring Pharmaceuticals, Inc.	Method of treating a brain tumor
CN107530341B (zh)	2015-03-06	2021-10-01	大连万春布林医药有限公司	治疗与ras突变相关的癌症的方法
JP6815686B2 (ja)	2015-03-10	2021-01-20	オーリジーンディスカバリーテクノロジーズリミテッドＡｕｒｉｇｅｎｅＤｉｓｃｏｖｅｒｙＴｅｃｈｎｏｌｏｇｉｅｓＬｉｍｉｔｅｄ	免疫調節剤としての１，２，４−オキサジアゾールおよびチアジアゾール化合物
US10449211B2 (en)	2015-03-10	2019-10-22	Aduro Biotech, Inc.	Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
US9809625B2 (en)	2015-03-18	2017-11-07	Bristol-Myers Squibb Company	Immunomodulators
EP3735986A1 (en)	2015-03-23	2020-11-11	Jounce Therapeutics, Inc.	Antibodies to icos
KR102610592B1 (ko) *	2015-03-30	2023-12-07	주식회사 에스티큐브	당화 pd-l1에 특이적인 항체 및 그의 사용 방법
EP3277716B1 (en)	2015-04-03	2020-06-24	XOMA Technology Ltd.	Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2016164580A1 (en)	2015-04-07	2016-10-13	Novartis Ag	Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
EP3280464A4 (en)	2015-04-10	2018-09-26	President and Fellows of Harvard College	Immune cell trapping devices and methods for making and using the same
CN107743401B (zh)	2015-04-17	2021-08-24	百时美施贵宝公司	包含抗pd-1抗体和另外的抗体的组合的组合物
ES2844799T5 (en)	2015-04-17	2025-01-16	Merck Sharp & Dohme Llc	Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EP4234685A3 (en)	2015-04-17	2023-09-06	Novartis AG	Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
US9981239B2 (en)	2015-04-21	2018-05-29	Twist Bioscience Corporation	Devices and methods for oligonucleic acid library synthesis
US12128069B2 (en)	2015-04-23	2024-10-29	The Trustees Of The University Of Pennsylvania	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
KR20170140316A (ko)	2015-04-28	2017-12-20	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
WO2016176503A1 (en)	2015-04-28	2016-11-03	Bristol-Myers Squibb Company	Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
EP3294334B1 (en)	2015-05-11	2020-07-08	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
CN111234027A (zh)	2015-05-21	2020-06-05	哈普恩治疗公司	三特异性结合蛋白质及使用方法
US10815264B2 (en)	2015-05-27	2020-10-27	Southern Research Institute	Nucleotides for the treatment of cancer
CN107847583A (zh)	2015-05-28	2018-03-27	阿尔莫生物科技股份有限公司	用于治疗癌症的聚乙二醇化白细胞介素‑10
US20180155429A1 (en) *	2015-05-28	2018-06-07	Bristol-Myers Squibb Company	Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en)	2015-05-29	2021-08-03	Bristol-Myers Squibb Company	Treatment of renal cell carcinoma
PE20180672A1 (es)	2015-05-29	2018-04-19	Agenus Inc	Anticuerpos anti-ctla-4 y metodos de uso de los mismos
CN108025018B (zh)	2015-05-29	2021-08-17	默沙东公司	用于治疗癌症的pd-1拮抗剂和cpg-c型寡核苷酸的组合产品
CN107613980A (zh)	2015-05-31	2018-01-19	源生公司	用于免疫疗法的组合组合物
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
EP3307778A1 (en)	2015-06-12	2018-04-18	Bristol-Myers Squibb Company	Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
BR112017026704A2 (pt)	2015-06-12	2018-08-28	Macrogenics Inc	uso
JP6876629B2 (ja)	2015-06-16	2021-05-26	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Ｐｄ−ｌ１アンタゴニスト併用療法
CN107849145B (zh) *	2015-06-16	2021-10-26	基因泰克公司	抗cd3抗体及其使用方法
EP3310813A1 (en)	2015-06-17	2018-04-25	Novartis AG	Antibody drug conjugates
KR20180019725A (ko) *	2015-06-23	2018-02-26	메모리얼 슬로안-케터링 캔서 센터	신규의 피디 1 면역 조절제
CN107922497B (zh)	2015-06-24	2022-04-12	詹森药业有限公司	抗vista抗体和片段
KR20180023968A (ko)	2015-07-02	2018-03-07	셀진 코포레이션	혈액암 및 충실성 종양의 치료를 위한 병용 요법
GB201511790D0 (en)	2015-07-06	2015-08-19	Iomet Pharma Ltd	Pharmaceutical compound
WO2017011399A1 (en)	2015-07-13	2017-01-19	Beyondspring Pharmaceuticals, Inc	Plinabulin compositions
CN108368170B (zh)	2015-07-13	2022-04-15	西托姆克斯治疗公司	抗pd-1抗体、可活化抗pd-1抗体及其使用方法
WO2017011666A1 (en)	2015-07-14	2017-01-19	Bristol-Myers Squibb Company	Method of treating cancer using immune checkpoint inhibitor
EP3943098A3 (en)	2015-07-16	2022-05-11	Biokine Therapeutics Ltd.	Compositions and methods for treating cancer
NZ739503A (en)	2015-07-16	2023-06-30	Bioxcel Therapeutics Inc	A novel approach for treatment of cancer using immunomodulation
WO2017015427A1 (en)	2015-07-21	2017-01-26	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
KR20180030911A (ko)	2015-07-29	2018-03-26	노파르티스 아게	Pd-1 길항제와 egfr 억제제의 조합물
BR112018000212A2 (pt)	2015-07-29	2018-09-04	Novartis Ag	uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
ES2878188T3 (es)	2015-07-29	2021-11-18	Novartis Ag	Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
PL3328419T3 (pl)	2015-07-30	2021-12-27	Macrogenics, Inc.	Cząsteczki wiążące pd-1 i sposoby ich zastosowania
EP3331918A1 (en)	2015-08-04	2018-06-13	GlaxoSmithKline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
CA2994635A1 (en)	2015-08-04	2017-02-09	Glaxosmithkline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
WO2017025498A1 (en)	2015-08-07	2017-02-16	Pieris Pharmaceuticals Gmbh	Novel fusion polypeptide specific for lag-3 and pd-1
EP3331919A1 (en)	2015-08-07	2018-06-13	GlaxoSmithKline Intellectual Property Development Limited	Combination therapy comprising anti ctla-4 antibodies
WO2017024465A1 (en) *	2015-08-10	2017-02-16	Innovent Biologics (Suzhou) Co., Ltd.	Pd-1 antibodies
NZ739488A (en) *	2015-08-11	2024-11-29	Wuxi Biologics Ireland Ltd	Novel anti-pd-1 antibodies
US11453697B1 (en)	2015-08-13	2022-09-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
TN2018000023A1 (en)	2015-08-13	2019-07-08	Merck Sharp & Dohme	Cyclic di-nucleotide compounds as sting agonists.
US11014983B2 (en)	2015-08-20	2021-05-25	Sutro Biopharma, Inc.	Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
KR20180038553A (ko)	2015-08-25	2018-04-16	아르모 바이오사이언시스 인코포레이티드	질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
EP3341732B1 (en)	2015-08-27	2023-07-12	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods for predicting the survival time of patients suffering from a lung cancer
PE20181322A1 (es)	2015-09-01	2018-08-14	Agenus Inc	Anticuerpo anti-pd1 y sus metodos de uso
CN117510633A (zh)	2015-09-02	2024-02-06	伊缪泰普有限公司	抗lag-3抗体
KR20180043835A (ko)	2015-09-03	2018-04-30	에일러론 테라퓨틱스 인코포레이티드	펩티도미메틱 매크로사이클 및 이의 용도
JP6905163B2 (ja)	2015-09-03	2021-07-21	ザトラスティーズオブザユニバーシティオブペンシルバニア	サイトカイン放出症候群を予測するバイオマーカー
CA2998169A1 (en)	2015-09-18	2017-03-23	Twist Bioscience Corporation	Oligonucleic acid variant libraries and synthesis thereof
KR20180058772A (ko)	2015-09-22	2018-06-01	트위스트 바이오사이언스 코포레이션	핵산 합성을 위한 가요성 기판
WO2017055326A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055325A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of nk cells in a tissue sample
WO2017055320A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055327A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of endothelial cells in a tissue sample
KR20180054824A (ko)	2015-09-29	2018-05-24	셀진 코포레이션	Pd-1 결합 단백질 및 이의 사용 방법
EP3356551B1 (en)	2015-09-29	2020-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining the metabolic status of b-lymphomas
WO2017055324A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055321A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055319A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of b cells in a tissue sample
WO2017055322A1 (en)	2015-09-29	2017-04-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of neutrophils in a tissue sample
ES2941968T3 (es)	2015-10-01	2023-05-29	The Whitehead Institute For Biomedical Res	Marcaje de anticuerpos
EP3355875B1 (en)	2015-10-01	2021-09-29	Gilead Sciences, Inc.	Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
WO2017055404A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies specific for pd1 and tim3
UA123826C2 (uk)	2015-10-02	2021-06-09	Ф. Хоффманн-Ля Рош Аг	Антитіла до pd1 та способи їх застосування
JP7320944B2 (ja)	2015-10-08	2023-08-04	マクロジェニクス，インコーポレーテッド	Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
EP3362074B1 (en)	2015-10-16	2023-08-09	President and Fellows of Harvard College	Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US20180318365A1 (en)	2015-10-19	2018-11-08	Cold Genesys, Inc.	Methods of treating solid or lymphatic tumors by combination therapy
KR20180066236A (ko)	2015-10-22	2018-06-18	조운스 테라퓨틱스, 인크.	Icos 발현을 계측하기 위한 유전자 특질
CN105238762A (zh) *	2015-10-26	2016-01-13	无锡傲锐东源生物科技有限公司	抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
MA44334A (fr)	2015-10-29	2018-09-05	Novartis Ag	Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN106632674B (zh) *	2015-10-30	2018-11-16	泽达生物医药有限公司	一种抗pd-1单克隆抗体、其药物组合物及其用途
MA43163A (fr)	2015-11-02	2018-09-12	Five Prime Therapeutics Inc	Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer
LT3370768T (lt)	2015-11-03	2022-05-25	Janssen Biotech, Inc.	Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
CA3003969A1 (en)	2015-11-06	2017-05-11	Orionis Biosciences Nv	Bi-functional chimeric proteins and uses thereof
JP2018538263A (ja)	2015-11-18	2018-12-27	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体の組合せを用いる肺癌の処置法
EP3380523A1 (en)	2015-11-23	2018-10-03	Five Prime Therapeutics, Inc.	Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
TWI717432B (zh)	2015-12-02	2021-02-01	美商艾吉納斯公司	抗體和使用彼之方法
EP3383412A4 (en) *	2015-12-02	2019-06-05	Stcube, Inc.	SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF
WO2017093933A1 (en)	2015-12-03	2017-06-08	Glaxosmithkline Intellectual Property Development Limited	Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (en)	2015-12-08	2017-06-15	Glaxosmithkline Intellectual Property Development Limited	Benzothiadiazine compounds
CN105837692A (zh) *	2015-12-10	2016-08-10	苏州佰通生物科技有限公司	一种阻断免疫检测点的嵌合抗原受体及其应用
MA44082A (fr)	2015-12-14	2018-10-24	Macrogenics Inc	Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN108430499B (zh)	2015-12-15	2022-07-19	肿瘤免疫股份有限公司	嵌合和人源化抗人类ctla4单克隆抗体和其用途
US10538497B2 (en)	2015-12-15	2020-01-21	Merck Sharp & Dohme Corp.	Compounds as indoleamine 2,3-dioxygenase inhibitors
US10392442B2 (en)	2015-12-17	2019-08-27	Bristol-Myers Squibb Company	Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
BR112018012138A2 (pt)	2015-12-17	2018-12-04	Novartis Ag	moléculas de anticorpo para pd-1 e usos das mesmas
CN109069623A (zh)	2015-12-18	2018-12-21	诺华股份有限公司	靶向CD32b的抗体及其使用方法
ES2954153T3 (es)	2015-12-22	2023-11-20	Regeneron Pharma	Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer
ES2844374T3 (es)	2015-12-22	2021-07-22	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
MA44140A (fr)	2015-12-22	2021-05-19	Dana Farber Cancer Inst Inc	Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
CN105669864B (zh) *	2015-12-23	2018-10-16	杭州尚健生物技术有限公司	抗人程序性死亡受体1抗体及其制备方法和用途
EP3400443B1 (en)	2016-01-04	2020-09-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
CN115350279A (zh)	2016-01-07	2022-11-18	博笛生物科技有限公司	用于治疗肿瘤的抗-her2组合
CN115554406A (zh)	2016-01-07	2023-01-03	博笛生物科技有限公司	用于治疗肿瘤的抗-cd20组合
CN106943597A (zh)	2016-01-07	2017-07-14	博笛生物科技（北京）有限公司	用于治疗肿瘤的抗-egfr组合
BR112018013884A2 (pt)	2016-01-08	2018-12-18	Celgene Corp	formulações de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
CA3010794A1 (en)	2016-01-08	2017-07-13	Celgene Corporation	Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
SG11201805779TA (en)	2016-01-08	2018-08-30	Celgene Corp	Antiproliferative compounds, and their pharmaceutical compositions and uses
US10889643B2 (en)	2016-01-11	2021-01-12	Universität Zürich	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
US11214617B2 (en)	2016-01-22	2022-01-04	MabQuest SA	Immunological reagents
EP3405497A2 (en) *	2016-01-22	2018-11-28	Mabquest SA	Immunological reagents
WO2017129763A1 (en)	2016-01-28	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
ES2924741T3 (es)	2016-01-28	2022-10-10	Inst Nat Sante Rech Med	Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario
US10918737B2 (en)	2016-01-28	2021-02-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of cancer
WO2017133175A1 (en) *	2016-02-04	2017-08-10	Nanjing Legend Biotech Co., Ltd.	Engineered mammalian cells for cancer therapy
DK3411065T3 (da)	2016-02-05	2021-07-05	Orionis Biosciences BV	Clec9a-bindingsmidler
CN109072197A (zh)	2016-02-06	2018-12-21	哈佛学院校长同事会	重塑造血巢以重建免疫
CA3013467A1 (en)	2016-02-08	2017-08-17	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
WO2017137830A1 (en)	2016-02-12	2017-08-17	Janssen Pharmaceutica Nv	Anti-vista (b7h5) antibodies
BR112018015690A2 (pt)	2016-02-17	2018-12-26	Novartis Ag	anticorpos tgfbeta 2
US20200270265A1 (en)	2016-02-19	2020-08-27	Novartis Ag	Tetracyclic pyridone compounds as antivirals
RU2018133708A (ru)	2016-02-26	2020-03-26	Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)	Антитела, обладающие специфичностью к btla, и их использование
EP3423488A4 (en)	2016-02-29	2019-11-06	Foundation Medicine, Inc.	METHOD FOR THE TREATMENT OF CANCER
US10143746B2 (en)	2016-03-04	2018-12-04	Bristol-Myers Squibb Company	Immunomodulators
JP2019513347A (ja)	2016-03-04	2019-05-30	ノバルティスアーゲー	複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
WO2017155981A1 (en)	2016-03-07	2017-09-14	Massachusetts Institute Of Technology	Protein-chaperoned t-cell vaccines
US11497781B2 (en)	2016-03-10	2022-11-15	Cg Oncology, Inc.	Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017153952A1 (en)	2016-03-10	2017-09-14	Glaxosmithkline Intellectual Property Development Limited	5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
BR112018068461A2 (pt)	2016-03-15	2019-01-22	Mersana Therapeutics Inc	conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
WO2017160975A1 (en) *	2016-03-16	2017-09-21	Bristol-Myers Squibb Company	Methods of diagnosing and treating lupus
CN110753755B (zh)	2016-03-21	2023-12-29	丹娜法伯癌症研究院	T细胞耗竭状态特异性基因表达调节子及其用途
EP3432924A1 (en)	2016-03-23	2019-01-30	Novartis AG	Cell secreted minibodies and uses thereof
EP3433257B1 (en)	2016-03-24	2023-10-11	Novartis AG	Alkynyl nucleoside analogs as inhibitors of human rhinovirus
US11760803B2 (en)	2016-03-24	2023-09-19	Takeda Pharmaceutical Company Limited	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3225253A1 (en)	2016-04-01	2017-10-04	Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts	Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
WO2017173334A1 (en)	2016-04-01	2017-10-05	Checkmate Pharmaceuticals, Inc.	Fc receptor-mediated drug delivery
CN107286242B (zh)	2016-04-01	2019-03-22	中山康方生物医药有限公司	抗pd-1的单克隆抗体
US11209441B2 (en)	2016-04-05	2021-12-28	Bristol-Myers Squibb Company	Cytokine profiling analysis
US10358463B2 (en)	2016-04-05	2019-07-23	Bristol-Myers Squibb Company	Immunomodulators
BR112018070602A2 (pt)	2016-04-07	2019-02-05	Glaxosmithkline Ip Dev Ltd	composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
MX2018012333A (es)	2016-04-07	2019-03-07	Glaxosmithkline Ip Dev Ltd	Amidas heterociclicas utiles como moduladores de proteinas.
EP3445391A1 (en)	2016-04-13	2019-02-27	Vivia Biotech S.L.	Ex vivo bite-activated t cells
RU2018137110A (ru)	2016-04-13	2020-05-13	Оримабс Лтд.	Антитела против psma и их применение
UA125382C2 (uk)	2016-04-15	2022-03-02	Імьюнекст Інк.	Антитіла проти людського vista та їх застосування
EP3449921B1 (en)	2016-04-28	2023-05-31	Eisai R&D Management Co., Ltd.	Eribulin for inhibiting tumor growth
US20190298824A1 (en)	2016-05-04	2019-10-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv	Albumin-binding immunomodulatory compositions and methods of use thereof
AU2017260854B2 (en)	2016-05-05	2020-01-30	Glaxosmithkline Intellectual Property (No.2) Limited	Enhancer of Zeste Homolog 2 inhibitors
US11753463B2 (en)	2016-05-13	2023-09-12	Orionis Biosciences BV	Therapeutic targeting of non-cellular structures
EP3243832A1 (en)	2016-05-13	2017-11-15	F. Hoffmann-La Roche AG	Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CA3023883A1 (en)	2016-05-13	2017-11-16	Orionis Biosciences Nv	Targeted mutant interferon-beta and uses thereof
TWI786044B (zh)	2016-05-13	2022-12-11	美商再生元醫藥公司	藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
CA3020649A1 (en)	2016-05-18	2017-11-23	Boehringer Ingelheim International Gmbh	Anti pd-1 and anti-lag3 antibodies for cancer treatment
CN105968200B (zh)	2016-05-20	2019-03-15	瑞阳(苏州)生物科技有限公司	抗人pd-l1人源化单克隆抗体及其应用
WO2017200969A1 (en)	2016-05-20	2017-11-23	Eli Lilly And Company	Combination therapy with notch and pd-1 or pd-l1 inhibitors
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
CN106008714B (zh) *	2016-05-24	2019-03-15	瑞阳(苏州)生物科技有限公司	抗人pd-1人源化单克隆抗体及其应用
EP3463452A1 (en)	2016-05-24	2019-04-10	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2017202949A1 (en)	2016-05-25	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers
SG11201810023QA (en)	2016-05-27	2018-12-28	Agenus Inc	Anti-tim-3 antibodies and methods of use thereof
SG11201810454YA (en)	2016-06-02	2018-12-28	Bristol Myers Squibb Co	Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
ES2965957T3 (es)	2016-06-02	2024-04-17	Ultimovacs Asa	Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer
EP4248990A3 (en)	2016-06-02	2024-01-03	Bristol-Myers Squibb Company	Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
KR20230118713A (ko)	2016-06-03	2023-08-11	브리스톨-마이어스 스큅 컴퍼니	종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
EP3988570A1 (en)	2016-06-03	2022-04-27	Bristol-Myers Squibb Company	Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
KR20190015407A (ko)	2016-06-03	2019-02-13	브리스톨-마이어스 스큅 컴퍼니	재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
IL263439B1 (en)	2016-06-06	2025-02-01	Beyondspring Pharmaceuticals Inc	Composition and method for reducing neutropenia
ES2913929T3 (es)	2016-06-08	2022-06-06	Glaxosmithkline Ip Dev Ltd	Compuestos químicos como inhibidores de la ruta de ATF4
EP3468948A1 (en)	2016-06-08	2019-04-17	GlaxoSmithKline Intellectual Property Development Limited	Chemical compounds
JP7185530B2 (ja)	2016-06-13	2022-12-07	トルクセラピューティクス，インコーポレイテッド	免疫細胞機能を促進するための方法および組成物
IL263542B2 (en) *	2016-06-14	2024-10-01	Xencor Inc	Bispecific antibodies inhibit immunological checkpoint
EA036243B1 (ru)	2016-06-14	2020-10-16	Новартис Аг	Кристаллическая форма (r)-4-(5-(циклопропилэтинил)изоксазол-3-ил)-n-гидрокси-2-метил-2-(метилсульфонил)бутанамида как антибактериальное средство
WO2017216686A1 (en)	2016-06-16	2017-12-21	Novartis Ag	8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en)	2016-06-16	2017-12-21	Novartis Ag	Pentacyclic pyridone compounds as antivirals
PE20190731A1 (es)	2016-06-20	2019-05-23	Incyte Corp	Compuestos heterociclicos como inmunomoduladores
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN109640999A (zh)	2016-06-24	2019-04-16	无限药品股份有限公司	组合疗法
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP6993056B2 (ja)	2016-07-05	2022-02-15	ベイジーンリミテッド	癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
WO2018011166A2 (en)	2016-07-12	2018-01-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for quantifying the population of myeloid dendritic cells in a tissue sample
KR20230156174A (ko)	2016-07-12	2023-11-13	레볼루션 메디슨즈, 인크.	다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CN115404196A (zh)	2016-07-13	2022-11-29	哈佛学院院长等	抗原呈递细胞模拟支架及其制备和使用方法
CA3031542A1 (en)	2016-07-20	2018-01-25	University Of Utah Research Foundation	Cd229 car t cells and methods of use thereof
KR20190028540A (ko)	2016-07-20	2019-03-18	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Perk 억제제로서의 이소퀴놀린 유도체
IL264486B1 (en)	2016-07-28	2024-12-01	Novartis Ag	Combination therapies of chimeric antigen receptors and PD-1 inhibitors
US20190269666A1 (en)	2016-07-29	2019-09-05	Eli Lilly And Company	Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
EP3490548A4 (en)	2016-08-01	2020-04-15	Molecular Templates, Inc.	ADMINISTRATION OF HYPOXIA-ACTIVATED DRUGS IN COMBINATION WITH IMMUNOMODULATORS FOR THE TREATMENT OF CANCER
CN109789197A (zh)	2016-08-03	2019-05-21	奈斯科尔公司	用于调节lair信号转导的组合物和方法
EP3494140A1 (en)	2016-08-04	2019-06-12	GlaxoSmithKline Intellectual Property Development Ltd	Anti-icos and anti-pd-1 antibody combination therapy
WO2018027524A1 (en)	2016-08-09	2018-02-15	Innovent Biologics (Suzhou) Co., Ltd.	Pd-1 antibody formulation
WO2018029336A1 (en)	2016-08-12	2018-02-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
PT3500299T (pt)	2016-08-19	2024-02-21	Beigene Switzerland Gmbh	Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CA3034769A1 (en)	2016-08-22	2018-03-01	Twist Bioscience Corporation	De novo synthesized nucleic acid libraries
CN106977602B (zh) *	2016-08-23	2018-09-25	中山康方生物医药有限公司	一种抗pd1单克隆抗体、其药物组合物及其用途
WO2018035710A1 (en)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
CN106967172B (zh)	2016-08-23	2019-01-08	康方药业有限公司	抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
US10323248B2 (en)	2016-09-01	2019-06-18	Chimera Bioengineering, Inc.	Gold optimized CAR T-cells
US11096924B2 (en)	2016-09-07	2021-08-24	Trustees Of Tufts College	Combination therapies using immuno-dash inhibitors and PGE2 antagonists
TW201811788A (zh)	2016-09-09	2018-04-01	瑞士商諾華公司	作為抗病毒劑之多環吡啶酮化合物
WO2018048975A1 (en)	2016-09-09	2018-03-15	Bristol-Myers Squibb Company	Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
EP3509634A1 (en)	2016-09-09	2019-07-17	TG Therapeutics Inc.	Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2018046738A1 (en)	2016-09-12	2018-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from cancer
WO2018046736A1 (en)	2016-09-12	2018-03-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from cancer
US9914783B1 (en)	2016-09-14	2018-03-13	Abbvie Biotherapeutics Inc.	Anti-PD-1 antibodies and their uses
WO2018053434A1 (en)	2016-09-16	2018-03-22	The Johns Hopkins University	Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
US10766958B2 (en)	2016-09-19	2020-09-08	Celgene Corporation	Methods of treating vitiligo using PD-1 binding antibodies
EP3515944A4 (en)	2016-09-19	2020-05-06	Celgene Corporation	METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
AU2017332161B9 (en)	2016-09-21	2024-08-22	The United States Government As Represented By The Department Of Veterans Affairs	Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
WO2018057526A2 (en)	2016-09-21	2018-03-29	Twist Bioscience Corporation	Nucleic acid based data storage
KR20240035625A (ko)	2016-09-21	2024-03-15	넥스트큐어 인코포레이티드	Siglec-15를 위한 항체 및 이의 사용 방법
EP4360714A3 (en)	2016-09-21	2024-07-24	Nextcure, Inc.	Antibodies for siglec-15 and methods of use thereof
WO2018055080A1 (en)	2016-09-22	2018-03-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
CA3036564A1 (en)	2016-09-23	2018-03-29	Elstar Therapeutics, Inc.	Multispecific antibody molecules comprising lambda and kappa light chains
JOP20190061A1 (ar)	2016-09-28	2019-03-26	Novartis Ag	مثبطات بيتا-لاكتاماز
SG10202008647TA (en)	2016-10-04	2020-10-29	Merck Sharp & Dohme	BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
IL265762B2 (en)	2016-10-06	2024-04-01	Merck Patent Gmbh	Dosing regimen of avelumab for the treatment of cancer
EP3523331A1 (en)	2016-10-07	2019-08-14	Novartis AG	Chimeric antigen receptors for the treatment of cancer
CN110022907A (zh)	2016-10-10	2019-07-16	国家生物技术研究所公司	非细胞毒性的修饰细胞及其用途
MA46529A (fr)	2016-10-11	2019-08-21	Agenus Inc	Anticorps anti-lag-3 et leurs procédés d'utilisation
KR20190082782A (ko)	2016-10-14	2019-07-10	머크 샤프 앤드 돔 코포레이션	요로상피암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
WO2018071576A1 (en)	2016-10-14	2018-04-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Treatment of tumors by inhibition of cd300f
TW201819380A (zh)	2016-10-18	2018-06-01	瑞士商諾華公司	作為抗病毒劑之稠合四環吡啶酮化合物
WO2018075447A1 (en)	2016-10-19	2018-04-26	The Trustees Of Columbia University In The City Of New York	Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
WO2018077893A1 (en)	2016-10-24	2018-05-03	Orionis Biosciences Nv	Targeted mutant interferon-gamma and uses thereof
EP3532504A1 (en)	2016-10-28	2019-09-04	Bristol-Myers Squibb Company	Methods of treating urothelial carcinoma using an anti-pd-1 antibody
JP2019533458A (ja)	2016-11-01	2019-11-21	アナプティスバイオインコーポレイティッド	プログラム死１（ｐｄ−１）に対する抗体
UY37463A (es)	2016-11-02	2018-05-31	Glaxosmithkline Ip No 2 Ltd	Proteínas de unión
US11124577B2 (en)	2016-11-02	2021-09-21	Engmab Sàrl	Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
MY200695A (en)	2016-11-03	2024-01-11	Bristol Myers Squibb Co	Activatable anti-ctla-4 antibodies and uses thereof
US10342785B2 (en)	2016-11-04	2019-07-09	Askat Inc.	Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
KR102526034B1 (ko)	2016-11-07	2023-04-25	브리스톨-마이어스 스큅 컴퍼니	면역조정제
IT201600111877A1 (it) *	2016-11-07	2018-05-07	Biouniversa Srl	Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
US20190345500A1 (en)	2016-11-14	2019-11-14	\|Nserm (Institut National De La Santé Et De La Recherche Médicale)	Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
US11279694B2 (en)	2016-11-18	2022-03-22	Sumitomo Dainippon Pharma Oncology, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
US20190365788A1 (en)	2016-11-21	2019-12-05	Idenix Pharmaceuticals Llc	Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
WO2018101448A1 (en)	2016-11-30	2018-06-07	Kyowa Hakko Kirin Co., Ltd.	Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
KR20190090822A (ko)	2016-12-01	2019-08-02	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	조합 요법
EP3548068A1 (en)	2016-12-01	2019-10-09	GlaxoSmithKline Intellectual Property Development Limited	Combination therapy
AU2017368332A1 (en)	2016-12-03	2019-06-13	Juno Therapeutics, Inc.	Methods for modulation of CAR-T cells
IL266918B2 (en)	2016-12-07	2024-03-01	Agenus Inc	Anti-ctla-4 antibodies and methods of use thereof
CN110300599B (zh)	2016-12-07	2024-07-02	艾吉纳斯公司	抗体和其使用方法
ES2970913T3 (es)	2016-12-08	2024-05-31	Lixte Biotechnology Inc	Oxabicicloheptanos para modulación de la respuesta inmunitaria
IL295660A (en)	2016-12-22	2022-10-01	Incyte Corp	Benzooxazole derivatives as immunomodulators
CN110869052A (zh)	2016-12-23	2020-03-06	维图生物制剂公司	癌症的治疗
US11248049B2 (en)	2016-12-23	2022-02-15	Remd Biotherapeutics, Inc.	Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
WO2018122249A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018122245A1 (en)	2016-12-28	2018-07-05	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
US11633393B2 (en)	2017-01-06	2023-04-25	Beyondspring Pharmaceuticals, Inc.	Tubulin binding compounds and therapeutic use thereof
TWI767976B (zh)	2017-01-09	2022-06-21	美商提薩羅有限公司	用抗pd-1抗體治療癌症之方法
EP3565560B1 (en)	2017-01-09	2024-05-29	OnkosXcel Therapeutics, LLC	Predictive and diagnostic methods for prostate cancer
EP3568412A2 (en)	2017-01-13	2019-11-20	Agenus Inc.	T cell receptors that bind to ny-eso-1 and methods of use thereof
WO2018134279A1 (en)	2017-01-18	2018-07-26	Pieris Pharmaceuticals Gmbh	Novel fusion polypeptides specific for lag-3 and pd-1
EP3570870A1 (en)	2017-01-20	2019-11-27	Novartis AG	Combination therapy for the treatment of cancer
CN117586401A (zh) *	2017-01-20	2024-02-23	大有华夏生物医药集团有限公司	抗pd-1抗体及其用途
TWI820013B (zh)	2017-01-23	2023-11-01	美商銳新醫藥公司	作為別構ｓｈｐ２抑制劑之雙環化合物
EP4230623A3 (en)	2017-01-23	2023-10-11	Revolution Medicines, Inc.	Pyridine compounds as allosteric shp2 inhibitors
WO2018137681A1 (en)	2017-01-25	2018-08-02	Beigene, Ltd.	Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
JP7062010B2 (ja)	2017-01-27	2022-05-02	セルジーンコーポレイション	３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
SG11201907023UA (en)	2017-02-01	2019-08-27	Beyondspring Pharmaceuticals Inc	Method of reducing neutropenia
JOP20190187A1 (ar)	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
US10906985B2 (en)	2017-02-06	2021-02-02	Orionis Biosciences, Inc.	Targeted engineered interferon and uses thereof
JP7476467B2 (ja)	2017-02-06	2024-05-01	オリオンズバイオサイエンスビーブイ	標的化キメラタンパク質及びその使用
WO2018146128A1 (en)	2017-02-07	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018146148A1 (en)	2017-02-07	2018-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	A method for predicting the response to checkpoint blockade cancer immunotherapy
KR20190115053A (ko)	2017-02-10	2019-10-10	노파르티스 아게	1-(4-아미노-5-브로모-6-(1h-피라졸-1-일)피리미딘-2-일)-1h-피라졸-4-올 및 암 치료에 있어서의 이의 용도
WO2018150326A1 (en)	2017-02-15	2018-08-23	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer
US20200291089A1 (en)	2017-02-16	2020-09-17	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
MX2019009772A (es)	2017-02-21	2019-12-02	Regeneron Pharma	Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
CN110892485B (zh)	2017-02-22	2024-03-22	特韦斯特生物科学公司	基于核酸的数据存储
EP3585813A1 (en) *	2017-02-22	2020-01-01	Sutro Biopharma, Inc.	Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3585431A4 (en)	2017-02-24	2020-12-16	MacroGenics, Inc.	BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
EP3585782A1 (en)	2017-02-27	2020-01-01	GlaxoSmithKline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
WO2018160538A1 (en)	2017-02-28	2018-09-07	Mersana Therapeutics, Inc.	Combination therapies of her2-targeted antibody-drug conjugates
US11161905B2 (en)	2017-03-04	2021-11-02	Xiangtan Tenghua Bioscience	Recombinant antibodies to programmed death 1 (PD-1) and uses thereof
WO2018163051A1 (en)	2017-03-06	2018-09-13	Novartis Ag	Methods of treatment of cancer with reduced ubb expression
EP3596469A1 (en)	2017-03-12	2020-01-22	Yeda Research and Development Co., Ltd.	Methods of diagnosing and prognosing cancer
WO2018167780A1 (en)	2017-03-12	2018-09-20	Yeda Research And Development Co. Ltd.	Methods of prognosing and treating cancer
US10894959B2 (en)	2017-03-15	2021-01-19	Twist Bioscience Corporation	Variant libraries of the immunological synapse and synthesis thereof
CN110520436A (zh)	2017-03-15	2019-11-29	潘迪恩治疗公司	靶向免疫耐受性
AU2018235944B2 (en)	2017-03-15	2024-01-04	Amgen Inc.	Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
EP3600427A1 (en)	2017-03-24	2020-02-05	INSERM - Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating melanoma
EP3601353A1 (en)	2017-03-31	2020-02-05	Five Prime Therapeutics, Inc.	Combination therapy for cancer using anti-gitr antibodies
IL269026B2 (en)	2017-03-31	2024-12-01	Bristol Myers Squibb Co	Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients
CN106987631A (zh) *	2017-04-01	2017-07-28	武汉赛云博生物科技有限公司	一种用于pd‑1/pd‑l1阻断治疗伴随诊断的免疫组测序技术
IL269395B2 (en)	2017-04-03	2025-01-01	Hoffmann La Roche	Immunoconjugation of anti-PD-1 antibody with IL-2 or IL-15 mutation
WO2018185618A1 (en)	2017-04-03	2018-10-11	Novartis Ag	Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
PE20191463A1 (es)	2017-04-05	2019-10-16	Hoffmann La Roche	Anticuerpos biespecificos de union especifica pd1 y lag3
US11603407B2 (en)	2017-04-06	2023-03-14	Regeneron Pharmaceuticals, Inc.	Stable antibody formulation
TWI788340B (zh)	2017-04-07	2023-01-01	美商必治妥美雅史谷比公司	抗icos促效劑抗體及其用途
MX2019012223A (es)	2017-04-13	2019-12-09	Agenus Inc	Anticuerpos anti-cd137 y metodos de uso de los mismos.
WO2018191654A1 (en)	2017-04-14	2018-10-18	Cold Genesys, Inc.	Methods of treating bladder cancer
AU2018255300B2 (en)	2017-04-18	2021-10-28	Tempest Therapeutics, Inc.	Bicyclic compounds and their use in the treatment of cancer
CN108728444A (zh)	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
AU2018256406A1 (en)	2017-04-19	2019-10-17	Marengo Therapeutics, Inc.	Multispecific molecules and uses thereof
CN106939049B (zh)	2017-04-20	2019-10-01	苏州思坦维生物技术股份有限公司	拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
ES2971065T3 (es)	2017-04-21	2024-06-03	Sillajen Inc	Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control
CN118515666A (zh)	2017-04-27	2024-08-20	博笛生物科技有限公司	2-氨基-喹啉衍生物
AR111419A1 (es)	2017-04-27	2019-07-10	Novartis Ag	Compuestos fusionados de indazol piridona como antivirales
AR111651A1 (es)	2017-04-28	2019-08-07	Novartis Ag	Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018201047A1 (en)	2017-04-28	2018-11-01	Elstar Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US20200055948A1 (en)	2017-04-28	2020-02-20	Novartis Ag	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018204363A1 (en)	2017-05-01	2018-11-08	Agenus Inc.	Anti-tigit antibodies and methods of use thereof
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es)	2017-05-02	2019-12-16	Merck Sharp & Dohme	Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
AR111658A1 (es)	2017-05-05	2019-08-07	Novartis Ag	2-quinolinonas tricíclicas como agentes antibacteriales
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
AU2018265856B2 (en)	2017-05-12	2023-04-27	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
WO2018208667A1 (en)	2017-05-12	2018-11-15	Merck Sharp & Dohme Corp.	Cyclic di-nucleotide compounds as sting agonists
JP7274426B2 (ja)	2017-05-16	2023-05-16	ブリストル－マイヤーズスクイブカンパニー	抗ｇｉｔｒアゴニスト抗体での癌の処置
AR111760A1 (es)	2017-05-19	2019-08-14	Novartis Ag	Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2018274216A1 (en)	2017-05-24	2019-12-12	Novartis Ag	Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215937A1 (en)	2017-05-24	2018-11-29	Novartis Ag	Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
US20200362058A1 (en)	2017-05-24	2020-11-19	Novartis Ag	Antibody-cytokine engrafted proteins and methods of use
AU2018273914A1 (en)	2017-05-24	2019-11-14	Pandion Operations, Inc.	Targeted immunotolerance
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20240146108A (ko)	2017-05-30	2024-10-07	브리스톨-마이어스 스큅 컴퍼니	Lag-3 양성 종양의 치료
AU2018275209A1 (en)	2017-05-30	2019-10-17	Bristol-Myers Squibb Company	Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
AU2018277559A1 (en)	2017-05-30	2019-10-17	Bristol-Myers Squibb Company	Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
US20210246227A1 (en)	2017-05-31	2021-08-12	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JOP20190279A1 (ar)	2017-05-31	2019-11-28	Novartis Ag	الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
CN111051346A (zh) *	2017-05-31	2020-04-21	斯特库伯株式会社	使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20240149982A (ko)	2017-06-01	2024-10-15	브리스톨-마이어스 스큅 컴퍼니	항-pd-1 항체를 사용하여 종양을 치료하는 방법
US20200181274A1 (en)	2017-06-01	2020-06-11	Novartis Ag	Bispecific antibodies that bind cd 123 cd3
WO2018223004A1 (en)	2017-06-01	2018-12-06	Xencor, Inc.	Bispecific antibodies that bind cd20 and cd3
KR20200054160A (ko)	2017-06-02	2020-05-19	주노 쎄러퓨티크스 인코퍼레이티드	입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
EP3630126A4 (en)	2017-06-02	2021-03-17	The Penn State Research Foundation	CERAMIDE NANOLIPOSOMES, COMPOSITIONS AND METHODS OF USE FOR IMMUNOTHERAPY
CN110997724A (zh)	2017-06-06	2020-04-10	斯特库伯株式会社	使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2018225093A1 (en)	2017-06-07	2018-12-13	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds as atf4 pathway inhibitors
JP2020523018A (ja)	2017-06-09	2020-08-06	プロビデンスヘルスアンドサービシーズ−オレゴン	がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
JP2020522555A (ja)	2017-06-09	2020-07-30	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	組み合わせ療法
WO2018231864A1 (en)	2017-06-12	2018-12-20	Twist Bioscience Corporation	Methods for seamless nucleic acid assembly
GB2578844A (en)	2017-06-12	2020-05-27	Twist Bioscience Corp	Methods for seamless nucleic acid assembly
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
US20200147099A1 (en)	2017-06-20	2020-05-14	Institut Curie	Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
ES2959860T3 (es)	2017-06-22	2024-02-28	Celgene Corp	Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Il-1beta binding antibodies for use in treating cancer
MX2019015885A (es)	2017-06-22	2020-09-10	Novartis Ag	Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
KR20200019865A (ko)	2017-06-22	2020-02-25	노파르티스 아게	암 치료에 사용하기 위한 il-1베타 결합 항체
JP7080501B2 (ja)	2017-06-23	2022-06-06	バーディーバイオファーマシューティカルズインコーポレイテッド	医薬品組成物
JP7206222B2 (ja)	2017-06-23	2023-01-17	ブリストル－マイヤーズスクイブカンパニー	Ｐｄ－１のアンタゴニストとして作用する免疫調節剤
EP3645740A4 (en) *	2017-06-25	2021-08-18	Systimmune, Inc.	ANTI-PD-1 ANTIBODIES AND PROCESSES FOR PREPARATION AND USE
WO2019001417A1 (en)	2017-06-26	2019-01-03	Beigene, Ltd.	IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
AU2018292618A1 (en)	2017-06-27	2019-12-19	Novartis Ag	Dosage regimens for anti-TIM-3 antibodies and uses thereof
JP2020526194A (ja)	2017-06-29	2020-08-31	ジュノーセラピューティクスインコーポレイテッド	免疫療法薬と関連する毒性を評価するためのマウスモデル
EP4201399A3 (en)	2017-06-30	2023-08-09	Celgene Corporation	Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
BR112020000086A2 (pt)	2017-07-03	2020-07-07	Glaxosmithkline Intellectual Property Development Limited	derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
EP3649106A1 (en)	2017-07-03	2020-05-13	GlaxoSmithKline Intellectual Property Development Limited	N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
SG11202000143PA (en)	2017-07-10	2020-02-27	Celgene Corp	Antiproliferative compounds and methods of use thereof
US11293066B2 (en)	2017-07-18	2022-04-05	Institut Gustave Roussy	Method for assessing the response to PD-1/PDL-1 targeting drugs
WO2019018730A1 (en)	2017-07-20	2019-01-24	Novartis Ag	DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
WO2019020593A1 (en)	2017-07-25	2019-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
WO2019021208A1 (en)	2017-07-27	2019-01-31	Glaxosmithkline Intellectual Property Development Limited	USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
CN111148996A (zh)	2017-07-28	2020-05-12	百时美施贵宝公司	用于检查点抑制剂的预测性外周血生物标志物
EP3661498A4 (en)	2017-08-04	2021-04-21	Merck Sharp & Dohme Corp.	STING THIOPHENE BENZO [B] AGONISTS FOR CANCER TREATMENT
JP2020529421A (ja)	2017-08-04	2020-10-08	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
CA3078605A1 (en)	2017-08-28	2019-03-07	Bristol-Myers Squibb Company	Tim-3 antagonists for the treatment and diagnosis of cancers
JP7387585B2 (ja)	2017-09-04	2023-11-28	アジェナスインコーポレイテッド	混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法
JP2020532991A (ja) *	2017-09-07	2020-11-19	オーガスタユニバーシティリサーチインスティテュート，インコーポレーテッド	プログラム細胞死タンパク質１に対する抗体
EP3678703A1 (en)	2017-09-07	2020-07-15	Revolution Medicines, Inc.	Shp2 inhibitor compositions and methods for treating cancer
UY37866A (es)	2017-09-07	2019-03-29	Glaxosmithkline Ip Dev Ltd	Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
EA202090562A1 (ru)	2017-09-11	2020-08-10	Твист Байосайенс Корпорейшн	Связывающие gpcr белки и их синтез
WO2019053617A1 (en)	2017-09-12	2019-03-21	Glaxosmithkline Intellectual Property Development Limited	CHEMICAL COMPOUNDS
US11497756B2 (en)	2017-09-12	2022-11-15	Sumitomo Pharma Oncology, Inc.	Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
EP3684410A1 (en)	2017-09-19	2020-07-29	Institut Curie	Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
CN109554349B (zh) *	2017-09-27	2022-06-24	亘喜生物科技（上海）有限公司	Pd-1基因表达沉默的工程化免疫细胞
WO2019061324A1 (en)	2017-09-29	2019-04-04	Curis Inc.	CRYSTALLINE FORMS OF IMMUNOMODULATORS
US11492375B2 (en)	2017-10-03	2022-11-08	Bristol-Myers Squibb Company	Cyclic peptide immunomodulators
EP3692034A1 (en)	2017-10-05	2020-08-12	GlaxoSmithKline Intellectual Property Development Limited	Modulators of stimulator of interferon genes (sting)
US20210238172A1 (en)	2017-10-05	2021-08-05	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides useful as protein modulators and methods of using the same
CN111225926A (zh) *	2017-10-10	2020-06-02	努玛治疗有限公司	靶向pdl1的抗体及其使用方法
EA202090536A1 (ru)	2017-10-11	2020-07-22	Ориджен Дискавери Текнолоджис Лимитед	Кристаллические формы 3-замещенного 1,2,4-оксадиазола
SG11202002941WA (en)	2017-10-12	2020-04-29	Revolution Medicines Inc	Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
US20200239577A1 (en)	2017-10-15	2020-07-30	Bristol-Myers Squibb Company	Methods of treating tumor
CA3079310A1 (en)	2017-10-18	2019-04-25	Vivia Biotech, S.L.	Bite-activated car-t cells
KR102637566B1 (ko)	2017-10-20	2024-02-16	트위스트 바이오사이언스 코포레이션	폴리뉴클레오타이드 합성을 위한 가열된 나노웰
WO2019081983A1 (en)	2017-10-25	2019-05-02	Novartis Ag	CD32B TARGETING ANTIBODIES AND METHODS OF USE
EP3703692A4 (en)	2017-11-01	2021-04-28	Merck Sharp & Dohme Corp.	Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019090003A1 (en)	2017-11-01	2019-05-09	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
MX2020004243A (es)	2017-11-01	2020-09-25	Juno Therapeutics Inc	Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
US12031975B2 (en)	2017-11-01	2024-07-09	Juno Therapeutics, Inc.	Methods of assessing or monitoring a response to a cell therapy
CA3080098A1 (en)	2017-11-03	2019-05-09	Aurigene Discovery Technologies Limited	Dual inhibitors of tim-3 and pd-1 pathways
JP7378395B2 (ja)	2017-11-06	2023-11-13	オーリジーンオンコロジーリミテッド	免疫調節のためのコンジョイントセラピー
BR112020008316A2 (pt)	2017-11-06	2020-10-20	Bristol-Myers Squibb Company	métodos para o tratamento de um tumor
CA3082383A1 (en)	2017-11-08	2019-05-16	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-pd-1 sequences
ES2939112T3 (es)	2017-11-10	2023-04-19	Armo Biosciences Inc	Composiciones y métodos de uso de interleucina-10 en combinación con inhibidores de vías de puntos de control inmunitario
JP7269928B2 (ja)	2017-11-14	2023-05-09	メルク・シャープ・アンド・ドーム・エルエルシー	インドールアミン２，３－ジオキシゲナーゼ（ｉｄｏ）阻害剤としての新規の置換ビアリール化合物
US11498904B2 (en)	2017-11-14	2022-11-15	Merck Sharp & Dohme Llc	Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
AU2018368731A1 (en)	2017-11-16	2020-05-14	Novartis Ag	Combination therapies
MX2020005128A (es)	2017-11-17	2020-07-27	Merck Sharp & Dohme	Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
EP3710455A1 (en)	2017-11-17	2020-09-23	Novartis AG	Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
WO2019101956A1 (en)	2017-11-24	2019-05-31	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Methods and compositions for treating cancers
EP3717021A1 (en)	2017-11-27	2020-10-07	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
CN111801334B (zh)	2017-11-29	2023-06-09	百济神州瑞士有限责任公司	使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
JP2021509009A (ja)	2017-11-30	2021-03-18	ノバルティスアーゲー	Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
JP7348899B2 (ja)	2017-12-08	2023-09-21	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性分子及びその使用
US11946094B2 (en)	2017-12-10	2024-04-02	Augusta University Research Institute, Inc.	Combination therapies and methods of use thereof
EP3724189B1 (en)	2017-12-15	2023-10-04	Revolution Medicines, Inc.	Polycyclic compounds as allosteric shp2 inhibitors
JP2021506260A (ja)	2017-12-15	2021-02-22	ジュノーセラピューティクスインコーポレイテッド	抗ｃｃｔ５結合分子およびその使用方法
WO2019123285A1 (en)	2017-12-20	2019-06-27	Novartis Ag	Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
US11685761B2 (en)	2017-12-20	2023-06-27	Merck Sharp & Dohme Llc	Cyclic di-nucleotide compounds as sting agonists
WO2019126691A1 (en)	2017-12-21	2019-06-27	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
CN111770759A (zh)	2017-12-28	2020-10-13	通用医疗公司	靶向cbm信号体复合物诱导调节性t细胞使肿瘤微环境发炎
CN109966487B (zh) *	2017-12-28	2023-08-25	上海复宏汉霖生物制药有限公司	一种包含抗pd-l1单克隆抗体的药物配制剂
WO2019134946A1 (en)	2018-01-04	2019-07-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma resistant
IL275818B2 (en)	2018-01-04	2024-10-01	Twist Bioscience Corp	Dna-based digital information storage
US11324774B2 (en)	2018-01-05	2022-05-10	Augusta University Research Institute, Inc.	Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
US20200368268A1 (en)	2018-01-08	2020-11-26	Novartis Ag	Immune-enhancing rnas for combination with chimeric antigen receptor therapy
SG11202005323SA (en)	2018-01-12	2020-07-29	Bristol Myers Squibb Co	Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
JP2021511372A (ja)	2018-01-16	2021-05-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｔｉｍ３に対する抗体で癌を処置する方法
CN111629731A (zh)	2018-01-22	2020-09-04	百时美施贵宝公司	治疗癌症的组合物和方法
WO2019144126A1 (en)	2018-01-22	2019-07-25	Pascal Biosciences Inc.	Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
EP3743447B1 (en)	2018-01-23	2024-03-27	Nextcure, Inc.	B7-h4 antibodies and methods of use thereof
AU2019212118A1 (en)	2018-01-24	2020-09-03	Beyondspring Pharmaceuticals, Inc.	Composition and method for reducing thrombocytopenia via the administration of plinabulin
US20200354424A1 (en)	2018-01-26	2020-11-12	Orionis Biosciences, Inc.	Xcr1 binding agents and uses thereof
EP3746117A1 (en)	2018-01-31	2020-12-09	Celgene Corporation	Combination therapy using adoptive cell therapy and checkpoint inhibitor
JP2021511793A (ja)	2018-01-31	2021-05-13	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
US20210038659A1 (en)	2018-01-31	2021-02-11	Novartis Ag	Combination therapy using a chimeric antigen receptor
US20200405806A1 (en)	2018-02-08	2020-12-31	Bristol-Myers Squibb Company	Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
TW202438530A (zh)	2018-02-09	2024-10-01	日商小野藥品工業股份有限公司	雙特異性抗體
NL2020422B1 (en)	2018-02-12	2019-08-19	Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis	Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
US20200399383A1 (en)	2018-02-13	2020-12-24	Novartis Ag	Chimeric antigen receptor therapy in combination with il-15r and il15
US20210080467A1 (en)	2018-02-21	2021-03-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
KR20200139153A (ko)	2018-02-27	2020-12-11	인사이트 코포레이션	A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
CN111801331A (zh)	2018-02-28	2020-10-20	诺华股份有限公司	吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
US20210002373A1 (en)	2018-03-01	2021-01-07	Nextcure, Inc.	KLRG1 Binding Compositions and Methods of Use Thereof
TWI708787B (zh)	2018-03-02	2020-11-01	美商美國禮來大藥廠	Pd-1促效劑抗體及其用途
JP2021517127A (ja)	2018-03-06	2021-07-15	アンスティテュキュリィ	癌併用療法における使用のためのｓｅｔｄｂ１ヒストンメチルトランスフェラーゼの阻害剤
US20210030703A1 (en)	2018-03-12	2021-02-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
EP3765517A1 (en)	2018-03-14	2021-01-20	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en)	2018-03-14	2021-01-14	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
AU2019236865A1 (en)	2018-03-23	2020-10-01	Bristol-Myers Squibb Company	Antibodies against MICA and/or MICB and uses thereof
CN108530537B (zh) *	2018-03-29	2019-07-02	中国人民解放军军事科学院军事医学研究院	Pd-1/pd-l1信号通路抑制剂
WO2019185792A1 (en)	2018-03-29	2019-10-03	Philogen S.P.A	Cancer treatment using immunoconjugates and immune check-point inhibitors
CN111971306A (zh)	2018-03-30	2020-11-20	百时美施贵宝公司	治疗肿瘤的方法
US11702430B2 (en)	2018-04-03	2023-07-18	Merck Sharp & Dohme Llc	Aza-benzothiophene compounds as STING agonists
CA3095646A1 (en)	2018-04-03	2019-10-10	Merck Sharp & Dohme Corp.	Benzothiophenes and related compounds as sting agonists
KR20200140315A (ko)	2018-04-04	2020-12-15	브리스톨-마이어스 스큅 컴퍼니	항-cd27 항체 및 그의 용도
WO2019193541A1 (en)	2018-04-06	2019-10-10	Glaxosmithkline Intellectual Property Development Limited	Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en)	2018-04-06	2019-10-10	Glaxosmithkline Intellectual Property Development Limited	Heteroaryl derivatives of formula (i) as atf4 inhibitors
US12084655B2 (en)	2018-04-09	2024-09-10	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
SG11202009839PA (en)	2018-04-12	2020-11-27	Bristol Myers Squibb Co	Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
JP7361713B2 (ja)	2018-04-17	2023-10-16	テンペストセラピューティクス，インク．	二環式カルボキサミドおよびその使用方法
SG11202010159RA (en)	2018-04-18	2020-11-27	Xencor Inc	Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204665A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204179A1 (en)	2018-04-20	2019-10-24	Merck Sharp & Dohme Corp.	Novel substituted rig-i agonists: compositions and methods thereof
WO2019207030A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019210055A2 (en)	2018-04-26	2019-10-31	Agenus Inc.	Heat shock protein-binding peptide compositions and methods of use thereof
US20210047405A1 (en)	2018-04-27	2021-02-18	Novartis Ag	Car t cell therapies with enhanced efficacy
US12048745B2 (en)	2018-05-01	2024-07-30	Augusta University Research Institute, Inc.	Methods for detecting and reversing immune therapy resistance
EP3788369A1 (en)	2018-05-01	2021-03-10	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
FI3788047T3 (fi)	2018-05-04	2024-11-02	Incyte Corp	Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CN112752756B (zh)	2018-05-11	2024-06-25	因赛特公司	作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
US20210363216A1 (en)	2018-05-14	2021-11-25	Immunocore Limited	Bifunctional binding polypeptides
GB201807924D0 (en)	2018-05-16	2018-06-27	Ctxt Pty Ltd	Compounds
CA3100731A1 (en)	2018-05-18	2019-11-21	Incyte Corporation	Fused pyrimidine derivatives as a2a / a2b inhibitors
SG11202011467RA (en)	2018-05-18	2020-12-30	Twist Bioscience Corp	Polynucleotides, reagents, and methods for nucleic acid hybridization
CA3101050A1 (en)	2018-05-23	2019-11-28	Celgene Corporation	Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use
SG11202011568XA (en)	2018-05-23	2020-12-30	Celgene Corp	Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
TW202017569A (zh)	2018-05-31	2020-05-16	美商佩樂敦治療公司	用於抑制cd73之組合物及方法
US11352320B2 (en)	2018-05-31	2022-06-07	Merck Sharp & Dohme Corp.	Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
WO2019229699A1 (en)	2018-05-31	2019-12-05	Novartis Ag	Hepatitis b antibodies
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
CA3102256A1 (en)	2018-06-01	2019-12-05	Novartis Ag	Dosing of a bispecific antibody that bind cd123 and cd3
MA52785A (fr)	2018-06-01	2021-04-14	Novartis Ag	Molécules de liaison dirigées contre bcma et leurs utilisations
US20210221908A1 (en)	2018-06-03	2021-07-22	Lamkap Bio Beta Ltd.	Bispecific antibodies against ceacam5 and cd47
SG11202011830SA (en)	2018-06-13	2020-12-30	Novartis Ag	Bcma chimeric antigen receptors and uses thereof
CN112638375A (zh)	2018-06-15	2021-04-09	旗舰创业创新五公司	通过后细胞信号传导因子的调节来增加免疫活性
JP7097465B2 (ja)	2018-06-19	2022-07-07	アルモ・バイオサイエンシーズ・インコーポレイテッド	キメラ抗原受容体細胞療法と併用するｉｌ－１０剤の組成およびその使用方法
JP2021527714A (ja)	2018-06-20	2021-10-14	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	抗ｐｄ−１抗体及びその使用
TW202005985A (zh)	2018-06-21	2020-02-01	美商再生元醫藥公司	用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
WO2020005068A2 (en)	2018-06-29	2020-01-02	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
AU2019297451A1 (en)	2018-07-03	2021-01-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
EP3818146A4 (en) *	2018-07-04	2022-10-19	Cytoimmune Therapeutics, Inc.	COMPOSITIONS AND METHODS OF IMMUNOTHERAPY TARGETING FLT3, PD-1 AND/OR PD-L1
GEP20237560B (en)	2018-07-05	2023-10-25	Incyte Corp	Fused pyrazine derivatives as a2a / a2b inhibitors
JP2021529814A (ja)	2018-07-09	2021-11-04	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＤｅｖｅｌｏｐｍｅｎｔＬｉｍｉｔｅｄ	化学化合物
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN119241499A (zh)	2018-07-10	2025-01-03	诺华股份有限公司	3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
GB201811408D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	CD137 Binding Molecules
US20210277135A1 (en)	2018-07-13	2021-09-09	Bristol-Myers Squibb Company	Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
MA53381A (fr)	2018-07-24	2021-06-02	Amgen Inc	Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
CN112739371A (zh)	2018-07-26	2021-04-30	百时美施贵宝公司	用于治疗癌症的lag-3组合疗法
WO2020021061A1 (en)	2018-07-26	2020-01-30	Pieris Pharmaceuticals Gmbh	Humanized anti-pd-1 antibodies and uses thereof
EP3833383A1 (en)	2018-08-06	2021-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers
WO2020030571A1 (en)	2018-08-06	2020-02-13	Glaxosmithkline Intellectual Property Development Limited	Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020031107A1 (en)	2018-08-08	2020-02-13	Glaxosmithkline Intellectual Property Development Limited	Chemical compounds
WO2020033791A1 (en)	2018-08-09	2020-02-13	Verseau Therapeutics, Inc.	Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CA3106881A1 (en)	2018-08-27	2020-03-05	Pieris Pharmaceuticals Gmbh	Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
WO2020044206A1 (en)	2018-08-29	2020-03-05	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors for use in the treatment cancer
CN112996805A (zh)	2018-08-30	2021-06-18	Hcw生物科技公司	多链嵌合多肽和其用途
CN113365663A (zh)	2018-08-30	2021-09-07	Hcw生物科技公司	单链嵌合多肽和其用途
WO2020047462A2 (en)	2018-08-30	2020-03-05	HCW Biologics, Inc.	Methods of treating aging-related disorders
WO2020044252A1 (en)	2018-08-31	2020-03-05	Novartis Ag	Dosage regimes for anti-m-csf antibodies and uses thereof
US20210340279A1 (en)	2018-08-31	2021-11-04	Yale University	Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2020048942A1 (en)	2018-09-04	2020-03-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
WO2020049534A1 (en)	2018-09-07	2020-03-12	Novartis Ag	Sting agonist and combination therapy thereof for the treatment of cancer
CA3107137A1 (en) *	2018-09-07	2020-03-12	Pfizer Inc.	Anti-avb8 antibodies and compositions and uses thereof
WO2020053742A2 (en)	2018-09-10	2020-03-19	Novartis Ag	Anti-hla-hbv peptide antibodies
JP7467423B2 (ja)	2018-09-11	2024-04-15	キュリス，インコーポレイテッド	亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法
AU2019339777B2 (en)	2018-09-12	2022-09-01	Novartis Ag	Antiviral pyridopyrazinedione compounds
EP3849606A4 (en)	2018-09-13	2022-06-29	Merck Sharp & Dohme Corp.	Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
CN113396160A (zh)	2018-09-19	2021-09-14	国家医疗保健研究所	治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
US20220177587A1 (en)	2018-09-19	2022-06-09	Alpine Immune Sciences, Inc.	Methods and uses of variant cd80 fusion proteins and related constructs
WO2020061482A1 (en)	2018-09-21	2020-03-26	Harpoon Therapeutics, Inc.	Egfr binding proteins and methods of use
BR112021005769A2 (pt)	2018-09-25	2021-07-06	Harpoon Therapeutics Inc	proteínas de ligação a dll3 e métodos de uso
JP7465272B2 (ja)	2018-09-27	2024-04-10	マレンゴ・セラピューティクス，インコーポレーテッド	Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
US20210347851A1 (en)	2018-09-28	2021-11-11	Novartis Ag	Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en)	2018-09-28	2021-08-04	Novartis AG	Cd22 chimeric antigen receptor (car) therapies
MX2021003459A (es)	2018-09-29	2021-06-18	Novartis Ag	Proceso de fabricacion de un compuesto para la inhibicion de la actividad de shp2.
WO2020070053A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of inhibitors of stress granule formation for targeting the regulation of immune responses
KR20210069641A (ko)	2018-10-03	2021-06-11	젠코어 인코포레이티드	IL-12 이종이량체 Fc-융합 단백질
WO2020076799A1 (en)	2018-10-09	2020-04-16	Bristol-Myers Squibb Company	Anti-mertk antibodies for treating cancer
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
KR20210091710A (ko)	2018-10-12	2021-07-22	젠코어 인코포레이티드	PD-1 표적화 IL-15/IL-15Rα Fc 융합 단백질 및 병용요법에서의 이의 용도
CN112867803A (zh)	2018-10-16	2021-05-28	诺华股份有限公司	单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
CN118356479A (zh)	2018-10-17	2024-07-19	百欧林纳克斯有限公司	转移性胰脏腺癌的治疗
WO2020081381A1 (en)	2018-10-17	2020-04-23	Merck Sharp & Dohme Corp.	Novel arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
JP7595569B2 (ja)	2018-10-18	2024-12-06	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	固形腫瘍の処置のためのβｉｇ－ｈ３アンタゴニストと免疫チェックポイント阻害剤との組み合わせ
MX2021003903A (es)	2018-10-19	2021-06-04	Bristol Myers Squibb Co	Terapia combinada para el melanoma.
AU2019366321A1 (en)	2018-10-22	2021-05-13	Glaxosmithkline Intellectual Property Development Limited	Dosing
CN112912403A (zh)	2018-10-23	2021-06-04	百时美施贵宝公司	治疗肿瘤的方法
BR112021008012A2 (pt)	2018-10-29	2021-11-03	Mersana Therapeutics Inc	Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo
US20230053449A1 (en)	2018-10-31	2023-02-23	Novartis Ag	Dc-sign antibody drug conjugates
US12091405B2 (en)	2018-11-01	2024-09-17	Merck Sharp & Dohme Llc	Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
MX2021005024A (es)	2018-11-01	2021-07-21	Juno Therapeutics Inc	Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
MX2021005022A (es)	2018-11-01	2021-09-08	Juno Therapeutics Inc	Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
WO2020096871A1 (en)	2018-11-06	2020-05-14	Merck Sharp & Dohme Corp.	Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
TW202028222A (zh)	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
SMT202400252T1 (it)	2018-11-14	2024-07-09	Regeneron Pharma	Somministrazione intralesionale di inibitori di pd-1 il trattamentodel cancro della pelle.
KR20210104713A (ko)	2018-11-16	2021-08-25	주노 쎄러퓨티크스 인코퍼레이티드	Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
US11274150B2 (en)	2018-11-16	2022-03-15	Bristol-Myers Squibb Company	Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
US20220008515A1 (en)	2018-11-16	2022-01-13	Neoimmunetech, Inc.	Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
EP3880202A2 (en)	2018-11-16	2021-09-22	ArQule, Inc.	Pharmaceutical combination for treatment of cancer
EP3883576A4 (en)	2018-11-20	2022-06-22	Merck Sharp & Dohme Corp.	SUBSTITUTED AMINOTRIAZOLOPYRIMIDINES AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
WO2020104479A1 (en)	2018-11-20	2020-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
CA3119774A1 (en)	2018-11-20	2020-05-28	Merck Sharp & Dohme Corp.	Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020104496A1 (en)	2018-11-20	2020-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020109328A1 (en)	2018-11-26	2020-06-04	Debiopharm International S.A.	Combination treatment of hiv infections
EP3887823B1 (en)	2018-11-28	2024-01-17	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods and kit for assaying lytic potential of immune effector cells
EP3886845B1 (en)	2018-11-28	2024-09-04	Merck Sharp & Dohme LLC	Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
MX2021006156A (es)	2018-11-30	2021-09-08	Glaxosmithkline Ip Dev Ltd	Compuestos utiles en la terapia para el vih.
US20220088070A1 (en)	2018-11-30	2022-03-24	Juno Therapeutics, Inc.	Methods for treatment using adoptive cell therapy
JOP20210117A1 (ar)	2018-11-30	2023-01-30	Merck Sharp & Dohme	مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
WO2020117988A1 (en)	2018-12-04	2020-06-11	Tolero Pharmaceuticals, Inc.	Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
WO2020115262A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
JP2022511112A (ja)	2018-12-11	2022-01-28	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
WO2020120592A1 (en)	2018-12-12	2020-06-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating melanoma
GB201820547D0 (en)	2018-12-17	2019-01-30	Oxford Univ Innovation	Modified antibodies
US20220047556A1 (en)	2018-12-17	2022-02-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of sulconazole as a furin inhibitor
EP3898699A1 (en)	2018-12-19	2021-10-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
EP3897853A1 (en)	2018-12-20	2021-10-27	Xencor, Inc.	Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
JP2022514315A (ja)	2018-12-20	2022-02-10	ノバルティスアーゲー	３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
WO2020127885A1 (en)	2018-12-21	2020-06-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions for treating cancers and resistant cancers
NL2024544B1 (en)	2018-12-21	2021-03-15	Aim Immunotech Inc	Compositions And Methods For Cancer Therapy
WO2020128637A1 (en)	2018-12-21	2020-06-25	Novartis Ag	Use of il-1 binding antibodies in the treatment of a msi-h cancer
US20220025036A1 (en)	2018-12-21	2022-01-27	Novartis Ag	Use of il-1beta binding antibodies
US20200369762A1 (en)	2018-12-21	2020-11-26	Novartis Ag	Use of il-1beta binding antibodies
JOP20210159A1 (ar)	2018-12-21	2023-01-30	Novartis Ag	أجسام مضادة لـ pmel17 ومترافقات منها
EP3898674A1 (en)	2018-12-21	2021-10-27	Novartis AG	Use of il-1beta binding antibodies
CA3118182A1 (en)	2018-12-21	2020-06-25	Onxeo	New conjugated nucleic acid molecules and their uses
WO2020140012A1 (en)	2018-12-27	2020-07-02	Amgen Inc.	Lyophilized virus formulations
CN113574386A (zh)	2019-01-03	2021-10-29	国家医疗保健研究所	用于增强癌症患者的cd8+t细胞依赖性免疫应答的方法和药物组合物
SG11202107438WA (en)	2019-01-09	2021-08-30	Celgene Corp	Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
AU2020205643A1 (en)	2019-01-09	2021-08-19	Celgene Corporation	Antiproliferative compounds and second active agents for use in treating multiple myeloma
US11370777B2 (en)	2019-01-09	2022-06-28	Celgene Corporation	Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
EP3908299A4 (en) *	2019-01-11	2022-10-05	The Wistar Institute of Anatomy and Biology	MONOCLONAL DNA ANTIBODIES TO PD-1 FOR THE TREATMENT AND PREVENTION OF CANCER
KR20210121077A (ko)	2019-01-15	2021-10-07	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	돌연변이된 인터루킨-34 (il-34) 폴리펩티드 및 요법에서의 이의 용도
AU2020209766A1 (en)	2019-01-17	2021-07-08	Georgia Tech Research Corporation	Drug delivery systems containing oxidized cholesterols
US20220096651A1 (en)	2019-01-29	2022-03-31	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EP3918332A1 (en)	2019-01-30	2021-12-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
US20220117911A1 (en)	2019-02-04	2022-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating blood-brain barrier
MX2021009371A (es)	2019-02-12	2021-09-10	Sumitomo Pharma Oncology Inc	Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
WO2020165733A1 (en)	2019-02-12	2020-08-20	Novartis Ag	Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
EP3924520A1 (en)	2019-02-13	2021-12-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020168244A1 (en)	2019-02-15	2020-08-20	Incelldx, Inc.	Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
AU2020222346B2 (en)	2019-02-15	2021-12-09	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en)	2019-02-15	2020-08-20	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA202192260A1 (ru)	2019-02-15	2021-12-17	Инсайт Корпорейшн	Биомаркеры циклин-зависимой киназы 2 и их применение
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020169472A2 (en)	2019-02-18	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of inducing phenotypic changes in macrophages
US20220088075A1 (en)	2019-02-22	2022-03-24	The Trustees Of The University Of Pennsylvania	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
CA3131691A1 (en) *	2019-02-26	2020-09-03	Twist Bioscience Corporation	Variant nucleic acid libraries for antibody optimization
CA3131700A1 (en)	2019-02-27	2020-09-03	Ionis Pharmaceuticals, Inc.	Modulators of malat1 expression
MA55084A (fr)	2019-02-28	2022-01-05	Regeneron Pharma	Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
US11472791B2 (en)	2019-03-05	2022-10-18	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
MX2021010458A (es)	2019-03-05	2021-09-21	Amgen Inc	Uso de virus oncoliticos para el tratamiento del cancer.
CA3129963A1 (en)	2019-03-06	2020-09-10	Regeneron Pharmaceuticals, Inc.	Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2020183011A1 (en)	2019-03-14	2020-09-17	Institut Curie	Htr1d inhibitors and uses thereof in the treatment of cancer
EA202192555A1 (ru)	2019-03-19	2021-11-25	Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн	Комбинированная терапия для лечения рака
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (en)	2019-03-22	2022-01-26	Sumitomo Dainippon Pharma Oncology, Inc.	Compositions comprising pkm2 modulators and methods of treatment using the same
JP2022526960A (ja)	2019-03-28	2022-05-27	ブリストル－マイヤーズスクイブカンパニー	腫瘍を処置する方法
KR20210146348A (ko)	2019-03-28	2021-12-03	브리스톨-마이어스 스큅 컴퍼니	종양을 치료하는 방법
KR20220008811A (ko)	2019-03-29	2022-01-21	엥스띠뛰 퀴리	변형된 생물학적 활성을 갖는 인터류킨-2 변이체.
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
TW202102543A (zh)	2019-03-29	2021-01-16	美商安進公司	溶瘤病毒在癌症新輔助療法中之用途
WO2020201362A2 (en)	2019-04-02	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of predicting and preventing cancer in patients having premalignant lesions
US20220177465A1 (en)	2019-04-04	2022-06-09	Merck Sharp & Dohme Corp.	Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP3952850A1 (en)	2019-04-09	2022-02-16	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
US20220220480A1 (en)	2019-04-17	2022-07-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
US20220220565A1 (en)	2019-04-30	2022-07-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2020227159A2 (en)	2019-05-03	2020-11-12	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity
CN114096278A (zh)	2019-05-07	2022-02-25	英谬免疫股份有限公司	通过体外单采血增加对检查点抑制剂的反应
SG11202111262XA (en)	2019-05-13	2021-11-29	Regeneron Pharma	Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
CN114391015A (zh)	2019-05-16	2022-04-22	斯汀塞拉股份有限公司	苯并[b][1,8]萘啶乙酸衍生物和使用方法
CN114302875A (zh)	2019-05-16	2022-04-08	斯汀塞拉股份有限公司	氧代吖啶基乙酸衍生物及使用方法
KR20220035333A (ko)	2019-05-20	2022-03-22	팬디온 오퍼레이션스, 인코포레이티드	Madcam 표적 면역관용
EP3976090A1 (en)	2019-05-24	2022-04-06	Pfizer Inc.	Combination therapies using cdk inhibitors
CN114174538A (zh)	2019-05-30	2022-03-11	百时美施贵宝公司	适合于免疫肿瘤学疗法的多肿瘤基因特征
KR20220016155A (ko)	2019-05-30	2022-02-08	브리스톨-마이어스 스큅 컴퍼니	면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
JP2022534981A (ja)	2019-05-30	2022-08-04	ブリストル－マイヤーズスクイブカンパニー	細胞局在化シグネチャーおよび組み合わせ治療
US20220235132A1 (en) *	2019-06-05	2022-07-28	Anaptysbio, Inc.	Pd-1 agonist and method of using same
US20210038684A1 (en)	2019-06-11	2021-02-11	Alkermes Pharma Ireland Limited	Compositions and Methods for Cancer Immunotherapy
WO2020249873A1 (en)	2019-06-14	2020-12-17	Tilt Biotherapeutics Oy	Oncolytic adenovirus and checkpoint inhibitor combination therapy
JP2022536850A (ja)	2019-06-18	2022-08-19	ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー	Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
WO2020255009A2 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
JP2022537054A (ja)	2019-06-21	2022-08-23	エイチシーダブリューバイオロジックスインコーポレイテッド	多鎖キメラポリペプチドおよびその使用
WO2020257612A1 (en)	2019-06-21	2020-12-24	Twist Bioscience Corporation	Barcode-based nucleic acid sequence assembly
EP3990635A1 (en)	2019-06-27	2022-05-04	Rigontec GmbH	Design method for optimized rig-i ligands
BR112021026832A2 (pt)	2019-07-02	2022-05-10	Hutchinson Fred Cancer Res	Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
AU2020300619A1 (en)	2019-07-03	2022-01-27	Sumitomo Pharma Oncology, Inc.	Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
WO2021006199A1 (ja)	2019-07-05	2021-01-14	小野薬品工業株式会社	Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CN110384657A (zh) *	2019-07-15	2019-10-29	三峡大学	靶向PD-L1载miR-34a微泡的制备方法及在制备抑制宫颈癌的药物上的应用
GB201910304D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
GB201910305D0 (en)	2019-07-18	2019-09-04	Ctxt Pty Ltd	Compounds
US12036204B2 (en)	2019-07-26	2024-07-16	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
US11083705B2 (en)	2019-07-26	2021-08-10	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
CN114514032A (zh)	2019-08-02	2022-05-17	兰提欧派普有限公司	用于治疗癌症的血管紧张素2型(at2)受体激动剂
KR20220056176A (ko)	2019-08-02	2022-05-04	메르사나 테라퓨틱스, 인코포레이티드	암 치료를 위한 sting(인터페론 유전자의 자극인자) 작용제로서의 비스-[n-((5-카바모일)-1h-벤조[d]이미다졸-2-일)-피라졸-5-카복사미드] 유도체 및 관련 화합물
WO2021024020A1 (en)	2019-08-06	2021-02-11	Astellas Pharma Inc.	Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JPWO2021025140A1 (zh)	2019-08-08	2021-02-11
MX2022001732A (es)	2019-08-12	2022-05-06	Purinomia Biotech Inc	Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
EP4013750A1 (en)	2019-08-14	2022-06-22	Incyte Corporation	Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
GB201912107D0 (en)	2019-08-22	2019-10-09	Amazentis Sa	Combination
CA3152027A1 (en)	2019-08-30	2021-03-04	Agenus Inc.	Anti-cd96 antibodies and methods of use thereof
WO2021048292A1 (en)	2019-09-11	2021-03-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
EP4031540A1 (en)	2019-09-17	2022-07-27	Bial-R&D Investments, S.A.	Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
KR20220100859A (ko)	2019-09-17	2022-07-18	비알 - 알&디 인베스트먼츠, 에스.에이.	산성 세라미다아제 저해제로서의 치환된 n-헤테로시클릭 카르복사미드, 및 약제로서의 이의 용도
WO2021055612A1 (en)	2019-09-17	2021-03-25	BIAL-BioTech Investments, Inc.	Substituted imidazole carboxamides and their use in the treatment of medical disorders
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja)	2019-09-18	2022-11-22	ノバルティスアーゲー	Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
HUE067160T2 (hu)	2019-09-18	2024-10-28	Lamkap Bio Alpha AG	Bispecifikus antitestek CEACAM5 és CD3 ellen
KR20220064983A (ko)	2019-09-18	2022-05-19	노파르티스 아게	Nkg2d 융합 단백질 및 이의 용도
KR20220066334A (ko)	2019-09-22	2022-05-24	브리스톨-마이어스 스큅 컴퍼니	Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
AU2020355027A1 (en)	2019-09-23	2022-04-21	Twist Bioscience Corporation	Antibodies that bind CD3 Epsilon
AU2020356471A1 (en)	2019-09-23	2022-04-21	Twist Bioscience Corporation	Variant nucleic acid libraries for CRTH2
BR112022005655A2 (pt)	2019-09-25	2022-09-06	Bristol Myers Squibb Co	Biomarcador compósito para terapia para câncer
JP2022549495A (ja)	2019-09-25	2022-11-25	シージェンインコーポレイテッド	造血器がんの治療のための抗ｃｄ３０ａｄｃ、抗ｐｄ－１、および化学療法剤の併用
CN114667285A (zh)	2019-09-26	2022-06-24	诺华股份有限公司	抗病毒吡唑并吡啶酮化合物
CA3155173A1 (en)	2019-09-27	2021-04-01	Glaxosmithkline Intellectual Property Development Limited	Antigen binding proteins
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
CA3151322A1 (en)	2019-10-01	2021-04-08	Silverback Therapeutics, Inc.	Combination therapy with immune stimulatory conjugates
EP3800201A1 (en)	2019-10-01	2021-04-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd28h stimulation enhances nk cell killing activities
EP4037714A1 (en)	2019-10-03	2022-08-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating macrophages polarization
WO2021067863A2 (en)	2019-10-03	2021-04-08	Xencor, Inc.	Targeted il-12 heterodimeric fc-fusion proteins
WO2021064184A1 (en)	2019-10-04	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
CA3157681A1 (en)	2019-10-11	2021-04-15	Incyte Corporation	Bicyclic amines as cdk2 inhibitors
TW202128757A (zh)	2019-10-11	2021-08-01	美商建南德克公司	具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JOP20220083A1 (ar)	2019-10-14	2023-01-30	Incyte Corp	حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021074391A1 (en)	2019-10-17	2021-04-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing nasal intestinal type adenocarcinomas
CN114786680A (zh)	2019-10-21	2022-07-22	诺华股份有限公司	Tim-3抑制剂及其用途
WO2021079188A1 (en)	2019-10-21	2021-04-29	Novartis Ag	Combination therapies with venetoclax and tim-3 inhibitors
EP4048304A1 (en)	2019-10-22	2022-08-31	Institut Curie	Immunotherapy targeting tumor neoantigenic peptides
NL2024108B1 (en)	2019-10-26	2021-07-19	Vitroscan B V	Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
WO2021083060A1 (zh)	2019-10-28	2021-05-06	中国科学院上海药物研究所	五元杂环氧代羧酸类化合物及其医药用途
EP4051286A1 (en)	2019-10-29	2022-09-07	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods and compositions for treating uveal melanoma
TW202137984A (zh)	2019-10-29	2021-10-16	日商衛材R&D企管股份有限公司	用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
US20220390455A1 (en)	2019-11-05	2022-12-08	Bristol-Myers Squibb Company	M-protein assays and uses thereof
WO2021091946A1 (en)	2019-11-05	2021-05-14	Celgene Corporation	Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
WO2021092221A1 (en)	2019-11-06	2021-05-14	Bristol-Myers Squibb Company	Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092220A1 (en)	2019-11-06	2021-05-14	Bristol-Myers Squibb Company	Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
US20220411499A1 (en)	2019-11-08	2022-12-29	Bristol-Myers Squibb Company	LAG-3 Antagonist Therapy for Melanoma
KR20220101664A (ko)	2019-11-11	2022-07-19	인사이트 코포레이션	Pd-1/pd-l1 억제제의 염 및 결정질 형태
EP4058465A1 (en)	2019-11-14	2022-09-21	Cohbar Inc.	Cxcr4 antagonist peptides
JP2023502264A (ja)	2019-11-22	2023-01-23	スミトモファーマオンコロジー，インコーポレイテッド	固体用量医薬組成物
EP3824954A1 (en)	2019-11-22	2021-05-26	Centre National de la Recherche Scientifique	Device, apparatus and method for minibeam radiation therapy
AU2020385400A1 (en)	2019-11-22	2022-06-09	Theravance Biopharma R&D Ip, Llc	Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
AU2020394441A1 (en)	2019-11-26	2022-06-02	Novartis Ag	CD19 and CD22 chimeric antigen receptors and uses thereof
WO2021108025A1 (en)	2019-11-26	2021-06-03	Massachusetts Institute Of Technology	Cell-based cancer vaccines and cancer therapies
EP3831849A1 (en)	2019-12-02	2021-06-09	LamKap Bio beta AG	Bispecific antibodies against ceacam5 and cd47
CA3160739A1 (en)	2019-12-04	2021-06-10	Brian Goodman	Circular rna compositions and methods
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
US11897950B2 (en)	2019-12-06	2024-02-13	Augusta University Research Institute, Inc.	Osteopontin monoclonal antibodies
US20230074558A1 (en)	2019-12-06	2023-03-09	Mersana Therapeutics, Inc.	Dimeric compounds as sting agonists
CA3164124A1 (en)	2019-12-09	2021-06-17	Seagen Inc.	Combination therapy with liv1-adc and pd-1 antagonist
KR20220114063A (ko)	2019-12-13	2022-08-17	큐진 인크.	신규한 인터루킨-15 (ｉｌ-15) 융합 단백질 및 이의 용도
US20230114107A1 (en)	2019-12-17	2023-04-13	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US20230062932A1 (en)	2019-12-18	2023-03-02	Ctxt Pty Ltd	Compounds
IL294085A (en)	2019-12-19	2022-08-01	Bristol Myers Squibb Co	Combinations of dgk inhibitors and checkpoint antagonists
WO2021123243A1 (en)	2019-12-19	2021-06-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and vaccine compositions to treat cancers
KR20220116257A (ko)	2019-12-20	2022-08-22	노파르티스 아게	골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
WO2021138512A1 (en)	2020-01-03	2021-07-08	Incyte Corporation	Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4090770A1 (en)	2020-01-17	2022-11-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
CN114980902A (zh)	2020-01-17	2022-08-30	诺华股份有限公司	用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
IL294944A (en)	2020-01-28	2022-09-01	Genentech Inc	Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
CN115397859A (zh)	2020-01-30	2022-11-25	Ona疗法有限公司	治疗癌症和癌症转移的联合疗法
EP4100126A1 (en)	2020-02-05	2022-12-14	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
EP4100426A1 (en)	2020-02-06	2022-12-14	Bristol-Myers Squibb Company	Il-10 and uses thereof
JP2023519106A (ja)	2020-02-11	2023-05-10	エイチシーダブリューバイオロジックスインコーポレイテッド	クロマトグラフィー樹脂およびその使用
CN116670163A (zh)	2020-02-11	2023-08-29	Hcw生物科技公司	治疗年龄相关疾病和炎性疾病的方法
IL295083A (en)	2020-02-11	2022-09-01	Hcw Biologics Inc	Methods of activating regulatory t cells
EP4107187A4 (en)	2020-02-21	2024-07-03	Pandion Operations, Inc.	TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
WO2021171260A2 (en)	2020-02-28	2021-09-02	Novartis Ag	A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor or a pd-1 inhibitor
EP4110955A1 (en)	2020-02-28	2023-01-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021171264A1 (en)	2020-02-28	2021-09-02	Novartis Ag	Dosing of a bispecific antibody that binds cd123 and cd3
JP2023517011A (ja)	2020-03-05	2023-04-21	ネオティーエックスセラピューティクスリミテッド	免疫細胞を用いて癌を治療するための方法および組成物
WO2021177822A1 (en)	2020-03-06	2021-09-10	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Modulating anti-tumor immunity
KR20230017165A (ko)	2020-03-06	2023-02-03	인사이트 코포레이션	Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
KR20220151195A (ko)	2020-03-06	2022-11-14	오엔에이 테라퓨틱스 에스.엘.	항-cd36 항체 및 암을 치료하기 위한 이의 용도
US20230093147A1 (en)	2020-03-09	2023-03-23	President And Fellows Of Harvard College	Methods and compositions relating to improved combination therapies
MX2022011677A (es)	2020-03-20	2023-01-11	Orna Therapeutics Inc	Composiciones y métodos de arn circular.
MX2022011701A (es)	2020-03-23	2022-10-07	Bristol Myers Squibb Co	Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer.
CN115443269A (zh)	2020-03-31	2022-12-06	施万生物制药研发Ip有限责任公司	经取代的嘧啶和使用方法
CN115768485A (zh)	2020-04-02	2023-03-07	梅尔莎纳医疗公司	包含sting激动剂的抗体药物缀合物
MX2022012533A (es)	2020-04-10	2022-12-13	Juno Therapeutics Inc	Metodos y usos relacionados con terapia celular dise?ada con un receptor de antigeno quimerico dirigido al antigeno de maduracion de celulas b.
EP4136112A1 (en)	2020-04-14	2023-02-22	GlaxoSmithKline Intellectual Property Development Limited	Combination treatment for cancer
AU2021256652A1 (en)	2020-04-14	2022-11-03	Glaxosmithkline Intellectual Property Development Limited	Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
BR112022020841A2 (pt)	2020-04-16	2023-05-02	Incyte Corp	Inibidores de kras tricíclicos fundidos
IL296226A (en)	2020-04-21	2022-11-01	Novartis Ag	Dosing regimen for treating a disease modulated by csf-1r
TW202206100A (zh)	2020-04-27	2022-02-16	美商西健公司	癌症之治療
AU2021262794A1 (en)	2020-04-29	2022-11-24	Immunitybio, Inc.	Anti-CD26 proteins and uses thereof
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
WO2021224186A1 (en)	2020-05-04	2021-11-11	Institut Curie	New pyridine derivatives as radiosensitizers
EP4146345A2 (en)	2020-05-05	2023-03-15	Teon Therapeutics, Inc.	Cannabinoid receptor type 2 (cb2) modulators and uses thereof
CN115836054B (zh)	2020-05-06	2024-12-10	默沙东有限责任公司	Il4i1抑制剂和使用方法
WO2021231526A1 (en)	2020-05-13	2021-11-18	Incyte Corporation	Fused pyrimidine compounds as kras inhibitors
IL298019A (en)	2020-05-13	2023-01-01	Massachusetts Inst Technology	Compositions of polymeric microdevices and their use in cancer immunotherapy
CN115968377A (zh)	2020-05-20	2023-04-14	居里研究所	单域抗体及其在癌症治疗中的用途
US20230212231A1 (en)	2020-05-26	2023-07-06	Institut National De La Santé Et De La Recherche Médicale (Inserm)	Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CN115666724A (zh)	2020-05-26	2023-01-31	瑞泽恩制药公司	通过施用pd-1抑制剂抗体西米普利单抗来治疗宫颈癌的方法
EP4157923A2 (en)	2020-05-29	2023-04-05	President And Fellows Of Harvard College	Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
JP2023527869A (ja)	2020-06-01	2023-06-30	エイチシーダブリューバイオロジックスインコーポレイテッド	加齢関連障害の治療法
WO2021247003A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
US11767353B2 (en)	2020-06-05	2023-09-26	Theraly Fibrosis, Inc.	Trail compositions with reduced immunogenicity
US20210387983A1 (en)	2020-06-10	2021-12-16	Theravance Biopharma R&D Ip, Llc	Crystalline alk5 inhibitors and uses thereof
KR20230024967A (ko)	2020-06-11	2023-02-21	노파르티스 아게	Zbtb32 억제제 및 이의 용도
TW202214857A (zh)	2020-06-19	2022-04-16	法商昂席歐公司	新型結合核酸分子及其用途
EP4168007A1 (en)	2020-06-23	2023-04-26	Novartis AG	Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US20230293530A1 (en)	2020-06-24	2023-09-21	Yeda Research And Development Co. Ltd.	Agents for sensitizing solid tumors to treatment
WO2021262969A1 (en)	2020-06-24	2021-12-30	The General Hospital Corporation	Materials and methods of treating cancer
BR112022026090A2 (pt)	2020-06-25	2023-01-17	Celgene Corp	Métodos para tratar câncer com terapias de combinação
AU2021296917A1 (en)	2020-06-26	2023-02-02	Amgen Inc.	IL-10 muteins and fusion proteins thereof
EP4172323A1 (en)	2020-06-29	2023-05-03	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
CN115997123A (zh)	2020-06-30	2023-04-21	国家医疗保健研究所	用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
WO2022002874A1 (en)	2020-06-30	2022-01-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
ES2988714T3 (es)	2020-07-07	2024-11-21	Celgene Corp	Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas
AU2021306613A1 (en)	2020-07-07	2023-02-02	BioNTech SE	Therapeutic RNA for HPV-positive cancer
WO2022009157A1 (en)	2020-07-10	2022-01-13	Novartis Ag	Lhc165 and spartalizumab combinations for treating solid tumors
US20230266332A1 (en)	2020-07-28	2023-08-24	Inserm (Institut National De La Santè Et De La Recherch Médicale)	Methods and compositions for preventing and treating a cancer
WO2022029573A1 (en)	2020-08-03	2022-02-10	Novartis Ag	Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4200324A4 (en) *	2020-08-19	2024-10-02	Pandion Operations, Inc.	MULTIPARATOPIC ANTI-PD-1 ANTIBODIES AND THEIR USES
EP4204458A4 (en)	2020-08-26	2024-10-09	Marengo Therapeutics, Inc.	METHODS FOR DETECTION OF TRBC1 OR TRBC2
CA3168743A1 (en)	2020-08-26	2022-03-03	Matthew G. Fury	Methods of treating cancer by administering a pd-1 inhibitor
EP4204095A1 (en)	2020-08-28	2023-07-05	Bristol-Myers Squibb Company	Lag-3 antagonist therapy for hepatocellular carcinoma
WO2022047093A1 (en)	2020-08-28	2022-03-03	Incyte Corporation	Vinyl imidazole compounds as inhibitors of kras
EP4204020A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
CA3190660A1 (en)	2020-08-31	2022-03-03	George C. Lee	Cell localization signature and immunotherapy
WO2022043557A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
MX2023002570A (es)	2020-09-02	2023-05-19	Pharmabcine Inc	Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.
IL300975A (en)	2020-09-03	2023-04-01	Regeneron Pharma	Methods of treating cancer pain by administering a pd-1 inhibitor
EP4222171A1 (en)	2020-10-02	2023-08-09	Regeneron Pharmaceuticals, Inc.	Combination of antibodies for treating cancer with reduced cytokine release syndrome
US11767320B2 (en)	2020-10-02	2023-09-26	Incyte Corporation	Bicyclic dione compounds as inhibitors of KRAS
WO2022076318A1 (en)	2020-10-05	2022-04-14	Bristol-Myers Squibb Company	Methods for concentrating proteins
WO2022079270A1 (en)	2020-10-16	2022-04-21	Université D'aix-Marseille	Anti-gpc4 single domain antibodies
WO2022084325A1 (en)	2020-10-20	2022-04-28	Institut Curie	Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
WO2022084531A1 (en)	2020-10-23	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating glioma
JP2023548051A (ja)	2020-10-23	2023-11-15	ブリストル－マイヤーズスクイブカンパニー	肺がんのためのｌａｇ－３アンタゴニスト療法
AU2021369590A1 (en)	2020-10-28	2023-06-22	Ikena Oncology, Inc.	Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022092085A1 (ja)	2020-10-28	2022-05-05	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療用医薬組成物
AU2021373044A1 (en)	2020-11-06	2023-06-08	Incyte Corporation	Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
WO2022097060A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
WO2022099018A1 (en)	2020-11-06	2022-05-12	Incyte Corporation	Process of preparing a pd-1/pd-l1 inhibitor
WO2022099075A1 (en)	2020-11-06	2022-05-12	Incyte Corporation	Crystalline form of a pd-1/pd-l1 inhibitor
MX2023004941A (es)	2020-11-08	2023-07-12	Seagen Inc	Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
MX2023005570A (es)	2020-11-12	2023-05-29	Inst Nat Sante Rech Med	Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
WO2022101463A1 (en)	2020-11-16	2022-05-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
WO2022101484A1 (en)	2020-11-16	2022-05-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating uveal melanoma
WO2022101481A1 (en)	2020-11-16	2022-05-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating uveal melanoma
JP2023550402A (ja)	2020-11-18	2023-12-01	アンスティテュ・クリー	ビグアニジンの二量体及びその治療的使用
TW202227089A (zh)	2020-11-30	2022-07-16	大陸商杭州阿諾生物醫藥科技有限公司	用於治療ｐｉｋ３ｃａ突變癌症的組合療法
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
PH12023500013A1 (en)	2020-12-04	2024-03-11	Tidal Therapeutics Inc	Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
CA3204091A1 (en)	2020-12-08	2022-06-16	Infinity Pharmaceuticals, Inc.	Eganelisib for use in the treatment of pd-l1 negative cancer
TW202237119A (zh)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Ａｌｋ﹘５抑制劑和彼之用途
WO2022130206A1 (en)	2020-12-16	2022-06-23	Pfizer Inc.	TGFβr1 INHIBITOR COMBINATION THERAPIES
WO2022130348A1 (en)	2020-12-18	2022-06-23	Lamkap Bio Beta Ag	Bispecific antibodies against ceacam5 and cd47
WO2022135667A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Therapeutic rna for treating cancer
TW202245808A (zh)	2020-12-21	2022-12-01	德商拜恩迪克公司	用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en)	2020-12-21	2022-06-30	BioNTech SE	Treatment schedule for cytokine proteins
CA3196999A1 (en)	2020-12-28	2022-07-07	Masano HUANG	Methods of treating tumors
AU2021411486A1 (en)	2020-12-28	2023-06-29	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
KR20230157940A (ko)	2020-12-29	2023-11-17	인사이트 코포레이션	A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법
CA3204162A1 (en)	2021-01-11	2022-07-14	Robert Kastelein	Compositions and methods related to receptor pairing
WO2022152862A1 (en)	2021-01-14	2022-07-21	Institut Curie	Her2 single domain antibodies variants and cars thereof
WO2022162569A1 (en)	2021-01-29	2022-08-04	Novartis Ag	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
JP2024506557A (ja)	2021-01-29	2024-02-14	アイオバンスバイオセラピューティクス，インコーポレイテッド	修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
WO2022165403A1 (en)	2021-02-01	2022-08-04	Yale University	Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
EP4292596A1 (en)	2021-02-10	2023-12-20	Curon Biopharmaceutical (Shanghai) Co., Limited	Method and combination for treating tumors
WO2022174102A1 (en)	2021-02-12	2022-08-18	Synthorx, Inc.	Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
KR20230154230A (ko)	2021-03-02	2023-11-07	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Dnmt1 억제제로서의 치환된 피리딘
EP4301780A1 (en)	2021-03-05	2024-01-10	Leadartis, S.L.	Trimeric polypeptides and uses thereof in the treatment of cancer
WO2022189618A1 (en)	2021-03-12	2022-09-15	Institut Curie	Nitrogen-containing heterocycles as radiosensitizers
US20240165094A1 (en)	2021-03-17	2024-05-23	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating melanoma
CN117321418A (zh)	2021-03-18	2023-12-29	诺华股份有限公司	癌症生物标志物及其使用方法
US11859021B2 (en)	2021-03-19	2024-01-02	Icahn School Of Medicine At Mount Sinai	Compounds for regulating trained immunity, and their methods of use
KR20230159590A (ko)	2021-03-23	2023-11-21	리제너론 파아마슈티컬스, 인크.	Pd-1 억제제를 투여함에 의한 면역억제 또는 면역손상된 환자에서 암을 치료하는 방법
TW202304506A (zh)	2021-03-25	2023-02-01	日商安斯泰來製藥公司	涉及抗claudin 18.2抗體的組合治療以治療癌症
KR20240005700A (ko)	2021-03-29	2024-01-12	주노 쎄러퓨티크스 인코퍼레이티드	체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
EP4314060A1 (en)	2021-03-31	2024-02-07	GlaxoSmithKline Intellectual Property Development Limited	Antigen binding proteins and combinations thereof
KR20230165276A (ko)	2021-03-31	2023-12-05	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4314068A1 (en)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4319739A2 (en)	2021-04-08	2024-02-14	Nurix Therapeutics, Inc.	Combination therapies with cbl-b inhibitor compounds
WO2022216993A2 (en)	2021-04-08	2022-10-13	Marengo Therapeutics, Inc.	Multifuntional molecules binding to tcr and uses thereof
CN117730097A (zh)	2021-04-09	2024-03-19	思进公司	以抗tigit抗体治疗癌症的方法
EP4323405A1 (en)	2021-04-12	2024-02-21	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
MX2023012060A (es)	2021-04-13	2024-01-22	Nuvalent Inc	Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr.
EP4322938A1 (en)	2021-04-14	2024-02-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	New method to improve nk cells cytotoxicity
CA3216880A1 (en)	2021-04-16	2022-10-20	Novartis Ag	Antibody drug conjugates and methods for making thereof
EP4326333A1 (en)	2021-04-20	2024-02-28	Seagen Inc.	Modulation of antibody-dependent cellular cytotoxicity
WO2022223791A1 (en)	2021-04-23	2022-10-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cell senescence accumulation related disease
WO2022227015A1 (en)	2021-04-30	2022-11-03	Merck Sharp & Dohme Corp.	Il4i1 inhibitors and methods of use
EP4337763A1 (en)	2021-05-10	2024-03-20	Institut Curie	Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
US20240317859A1 (en)	2021-05-13	2024-09-26	Foundation For Biomedical Research And Innovation At Kobe	Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
WO2022242664A1 (en) *	2021-05-18	2022-11-24	Suzhou Kanova Biopharmaceutical Co., Ltd.	Anti-pd-1 polypeptides and their use
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
WO2022242737A1 (zh)	2021-05-21	2022-11-24	天津立博美华基因科技有限责任公司	药物组合及其用途
WO2022251359A1 (en)	2021-05-26	2022-12-01	Theravance Biopharma R&D Ip, Llc	Bicyclic inhibitors of alk5 and methods of use
TW202307210A (zh)	2021-06-01	2023-02-16	瑞士商諾華公司	Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
TW202313117A (zh)	2021-06-03	2023-04-01	美商欣爍克斯公司	包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
GB202107994D0 (en)	2021-06-04	2021-07-21	Kymab Ltd	Treatment of cancer
WO2022261018A1 (en)	2021-06-07	2022-12-15	Providence Health & Services - Oregon	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CN115466329A (zh) *	2021-06-11	2022-12-13	广东菲鹏制药股份有限公司	一种抗pd-1人源化抗体及其应用
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
KR20240026507A (ko)	2021-06-29	2024-02-28	플래그쉽 파이어니어링 이노베이션스 브이, 인크.	타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
US20240316005A1 (en)	2021-07-05	2024-09-26	Institut National de la Santé et de la Recherche Médicale	Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
KR20240032915A (ko)	2021-07-07	2024-03-12	인사이트 코포레이션	Kras의 저해제로서의 삼환식 화합물
US20240327544A1 (en)	2021-07-13	2024-10-03	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
JP2024529340A (ja)	2021-07-14	2024-08-06	シンセカインインコーポレイテッド	新生物疾患の細胞療法に使用するための方法および組成物
JP2024529347A (ja)	2021-07-14	2024-08-06	インサイト・コーポレイション	Ｋｒａｓの阻害剤としての三環式化合物
US20230139492A1 (en)	2021-07-19	2023-05-04	Regeneron Pharmaceuticals, Inc.	Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
EP4377348A1 (en)	2021-07-30	2024-06-05	Seagen Inc.	Treatment for cancer
EP4377344A1 (en)	2021-07-30	2024-06-05	Ona Therapeutics S.L.	Anti-cd36 antibodies and their use to treat cancer
WO2023012147A1 (en)	2021-08-03	2023-02-09	F. Hoffmann-La Roche Ag	Bispecific antibodies and methods of use
WO2023015198A1 (en)	2021-08-04	2023-02-09	Genentech, Inc.	Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
CA3227880A1 (en)	2021-08-05	2023-02-09	Marios SOTIROPOULOS	Scanning dynamic device for minibeams production
KR20240099138A (ko)	2021-08-23	2024-06-28	이뮤니타스 테라퓨틱스, 인크.	항-cd161 항체 및 그의 용도
JP2024534187A (ja)	2021-08-31	2024-09-18	インサイト・コーポレイション	Ｋｒａｓの阻害剤としてのナフチリジン化合物
TW202325306A (zh)	2021-09-02	2023-07-01	美商天恩治療有限公司	改良免疫細胞之生長及功能的方法
CN118201914A (zh)	2021-09-08	2024-06-14	雷多纳治疗公司	Papd5和/或papd7抑制剂4-氧代-1,4-二氢喹啉-3-甲酸衍生物
US20240391979A1 (en) *	2021-09-13	2024-11-28	Achelois Biopharma, Inc.	Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
US20240316061A1 (en)	2021-09-17	2024-09-26	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
WO2023049697A1 (en)	2021-09-21	2023-03-30	Incyte Corporation	Hetero-tricyclic compounds as inhibitors of kras
WO2023051926A1 (en)	2021-09-30	2023-04-06	BioNTech SE	Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
US12030884B2 (en)	2021-10-01	2024-07-09	Incyte Corporation	Pyrazoloquinoline KRAS inhibitors
TW202327595A (zh)	2021-10-05	2023-07-16	美商輝瑞大藥廠	用於治療癌症之氮雜內醯胺化合物的組合
WO2023057534A1 (en)	2021-10-06	2023-04-13	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 in combination
TW202333802A (zh)	2021-10-11	2023-09-01	德商拜恩迪克公司	用於肺癌之治療性rna(二)
CR20240197A (es)	2021-10-14	2024-08-07	Incyte Corp	Compuestos de quinolina como inhibidores de kras
EP4410842A1 (en)	2021-10-21	2024-08-07	Adlai Nortye Biopharma Co., Ltd.	Fusion polypeptide and use thereof
JP2024540106A (ja)	2021-10-28	2024-10-31	ライエル・イミュノファーマ・インコーポレイテッド	免疫細胞を培養するための方法
CA3224890A1 (en)	2021-10-29	2023-05-04	Bristol-Myers Squibb Company	Lag-3 antagonist therapy for hematological cancer
WO2023081730A1 (en)	2021-11-03	2023-05-11	Teon Therapeutics, Inc.	4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
WO2023078900A1 (en)	2021-11-03	2023-05-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023079428A1 (en)	2021-11-03	2023-05-11	Pfizer Inc.	Combination therapies using tlr7/8 agonist
WO2023083439A1 (en)	2021-11-09	2023-05-19	BioNTech SE	Tlr7 agonist and combinations for cancer treatment
US20230279153A1 (en) *	2021-11-11	2023-09-07	Regeneron Pharmaceuticals, Inc.	Cd20-pd1 binding molecules and methods of use thereof
US20250009916A1 (en)	2021-11-12	2025-01-09	Novartis Ag	Combination therapy for treating lung cancer
EP4435011A1 (en)	2021-11-15	2024-09-25	Institute Of Biophysics, Chinese Academy Of Sciences	Fusion protein construct taking interleukin 15 as active ingredient and use thereof
CN118765283A (zh)	2021-11-17	2024-10-11	国家健康科学研究所	通用沙贝病毒疫苗
WO2023089032A1 (en)	2021-11-19	2023-05-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
EP4436578A1 (en)	2021-11-22	2024-10-02	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023097211A1 (en)	2021-11-24	2023-06-01	The University Of Southern California	Methods for enhancing immune checkpoint inhibitor therapy
TW202329937A (zh)	2021-12-03	2023-08-01	美商英塞特公司	雙環胺ｃｋ１２抑制劑
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
US12084453B2 (en)	2021-12-10	2024-09-10	Incyte Corporation	Bicyclic amines as CDK12 inhibitors
CN118660964A (zh)	2021-12-16	2024-09-17	瓦莱里奥治疗公司	新型缀合核酸分子及其用途
WO2023122573A1 (en)	2021-12-20	2023-06-29	Synthorx, Inc.	Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023118165A1 (en)	2021-12-21	2023-06-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
AU2022418585A1 (en)	2021-12-22	2024-07-11	Incyte Corporation	Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
JP2025501238A (ja)	2021-12-30	2025-01-17	ネオイミューンテック，インコーポレイテッド	Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法
WO2023133424A2 (en) *	2022-01-05	2023-07-13	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
JP2025502061A (ja)	2022-01-07	2025-01-24	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	再発性卵巣癌を、二重特異性抗ｍｕｃ１６×抗ｃｄ３抗体単独で、または抗ｐｄ－１抗体と組み合わせて治療する方法
MX2024008831A (es)	2022-01-26	2024-07-25	Bristol Myers Squibb Co	Terapia combinada para carcinoma hepatocelular.
EP4469065A1 (en)	2022-01-28	2024-12-04	Iovance Biotherapeutics, Inc.	Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4466291A2 (en)	2022-01-28	2024-11-27	Georgiamune Inc.	Antibodies to programmed cell death protein 1 that are pd-1 agonists
EP4470565A1 (en)	2022-01-28	2024-12-04	OnQuality Pharmaceuticals China Ltd.	Method for preventing or treating disease or disorder associated with antineoplastic agent
EP4479388A1 (en)	2022-02-14	2024-12-25	Gilead Sciences, Inc.	Antiviral naphthyridinone compounds
WO2023154799A1 (en)	2022-02-14	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Combination immunotherapy for treating cancer
WO2023159102A1 (en)	2022-02-17	2023-08-24	Regeneron Pharmaceuticals, Inc.	Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
CN118715226A (zh)	2022-02-21	2024-09-27	上海岸阔医药科技有限公司	化合物及其用途
EP4482947A1 (en)	2022-02-24	2025-01-01	Amazentis SA	Uses of urolithins
WO2023164638A1 (en)	2022-02-25	2023-08-31	Bristol-Myers Squibb Company	Combination therapy for colorectal carcinoma
KR20240156626A (ko)	2022-03-02	2024-10-30	이뮤니티바이오, 인크.	췌장암의 치료 방법
WO2023168404A1 (en)	2022-03-04	2023-09-07	Bristol-Myers Squibb Company	Methods of treating a tumor
AR128717A1 (es)	2022-03-07	2024-06-05	Incyte Corp	Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
CN119156403A (zh)	2022-03-08	2024-12-17	阿伦蒂斯治疗股份公司	抗紧密连接蛋白-1抗体增加t细胞可用性的用途
EP4493280A1 (en)	2022-03-17	2025-01-22	Regeneron Pharmaceuticals, Inc.	Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
KR20240159621A (ko)	2022-03-18	2024-11-05	브리스톨-마이어스 스큅 컴퍼니	폴리펩티드를 단리하는 방법
WO2023180552A1 (en)	2022-03-24	2023-09-28	Institut Curie	Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
WO2023187024A1 (en)	2022-03-31	2023-10-05	Institut Curie	Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023192478A1 (en)	2022-04-01	2023-10-05	Bristol-Myers Squibb Company	Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2023196987A1 (en)	2022-04-07	2023-10-12	Bristol-Myers Squibb Company	Methods of treating tumor
EP4504244A1 (en)	2022-04-07	2025-02-12	Institut Curie	Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
EP4504245A1 (en)	2022-04-07	2025-02-12	Institut Curie	Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
US20230326022A1 (en)	2022-04-08	2023-10-12	Bristol-Myers Squibb Company	Machine Learning Identification, Classification, and Quantification of Tertiary Lymphoid Structures
WO2023213763A1 (en)	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023214325A1 (en)	2022-05-05	2023-11-09	Novartis Ag	Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
IL316628A (en)	2022-05-12	2024-12-01	Genmab As	Binding agents capable of binding to CD27 in combination therapy
CN119421723A (zh)	2022-05-16	2025-02-11	瑞泽恩制药公司	用双特异性抗PSMA x抗CD3抗体单独或与抗PD-1抗体组合治疗转移性去势抵抗性前列腺癌的方法
WO2023230554A1 (en)	2022-05-25	2023-11-30	Pfizer Inc.	Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
IL317203A (en)	2022-05-27	2025-01-01	Takeda Pharmaceuticals Co	CD38-binding fusion protein dosage
AR129423A1 (es)	2022-05-27	2024-08-21	Viiv Healthcare Co	Compuestos útiles en la terapia contra el hiv
AU2023281061A1 (en)	2022-06-02	2024-12-05	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
AR129560A1 (es)	2022-06-08	2024-09-04	Tidal Therapeutics Inc	Lípidos catiónicos ionizables y nanopartículas lipídicas, y métodos de síntesis y uso de los mismos
WO2023239768A1 (en)	2022-06-08	2023-12-14	Incyte Corporation	Tricyclic triazolo compounds as dgk inhibitors
IL316117A (en)	2022-06-16	2024-12-01	Lamkap Bio Beta Ltd	Combination drug regimen of anti-CEACAM5 and CD47 antigens and bispecific anti-CEACAM5 and CD3 antigens
WO2023250400A1 (en)	2022-06-22	2023-12-28	Juno Therapeutics, Inc.	Treatment methods for second line therapy of cd19-targeted car t cells
WO2023250430A1 (en)	2022-06-22	2023-12-28	Incyte Corporation	Bicyclic amine cdk12 inhibitors
AU2023300419A1 (en)	2022-07-01	2025-01-02	Transgene	Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024015731A1 (en)	2022-07-11	2024-01-18	Incyte Corporation	Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024015372A1 (en)	2022-07-14	2024-01-18	Teon Therapeutics, Inc.	Adenosine receptor antagonists and uses thereof
EP4310197A1 (en)	2022-07-21	2024-01-24	Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda	Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
AU2023317596A1 (en)	2022-08-02	2025-02-13	Regeneron Pharmaceuticals, Inc.	Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
AU2023320568A1 (en)	2022-08-05	2025-02-06	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for gprc5d and bcma
WO2024033399A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sk2 inhibitor for the treatment of pancreatic cancer
WO2024040175A1 (en)	2022-08-18	2024-02-22	Pulmatrix Operating Company, Inc.	Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024040264A1 (en)	2022-08-19	2024-02-22	Massachusetts Institute Of Technology	Compositions and methods for targeting dendritic cell lectins
WO2024052356A1 (en)	2022-09-06	2024-03-14	Institut National de la Santé et de la Recherche Médicale	Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024056716A1 (en)	2022-09-14	2024-03-21	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024068617A1 (en)	2022-09-26	2024-04-04	Institut Curie	Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
WO2024069009A1 (en)	2022-09-30	2024-04-04	Alentis Therapeutics Ag	Treatment of drug-resistant hepatocellular carcinoma
US20240270849A1 (en)	2022-10-03	2024-08-15	Regeneron Pharmaceuticals, Inc.	Methods of treating cancer with bispecific egfr xcd28 antibodies alone or in combination with anti-pd-1 antibodies
US20240174732A1 (en)	2022-10-05	2024-05-30	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024081736A2 (en)	2022-10-11	2024-04-18	Yale University	Compositions and methods of using cell-penetrating antibodies
WO2024084013A1 (en)	2022-10-20	2024-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination therapy for the treatment of cancer
WO2024086827A2 (en)	2022-10-20	2024-04-25	Repertoire Immune Medicines, Inc.	Cd8 t cell targeted il2
WO2024083988A1 (en)	2022-10-20	2024-04-25	Fundación Para La Investigación Médica Aplicada	Nanobodies for cancer therapy
WO2024084034A1 (en)	2022-10-21	2024-04-25	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024102722A1 (en)	2022-11-07	2024-05-16	Neoimmunetech, Inc.	Methods of treating a tumor with an unmethylated mgmt promoter
WO2024108100A1 (en)	2022-11-18	2024-05-23	Incyte Corporation	Heteroaryl fluoroalkenes as dgk inhibitors
WO2024112867A1 (en)	2022-11-23	2024-05-30	University Of Georgia Research Foundation, Inc.	Compositions and methods of use thereof for increasing immune responses
WO2024115725A1 (en)	2022-12-01	2024-06-06	BioNTech SE	Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
WO2024116140A1 (en)	2022-12-01	2024-06-06	Medimmune Limited	Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024129778A2 (en)	2022-12-13	2024-06-20	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024126457A1 (en)	2022-12-14	2024-06-20	Astellas Pharma Europe Bv	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
WO2024137776A1 (en)	2022-12-21	2024-06-27	Bristol-Myers Squibb Company	Combination therapy for lung cancer
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2024150177A1 (en)	2023-01-11	2024-07-18	Advesya	Treatment methods for solid tumors
WO2024151346A1 (en)	2023-01-12	2024-07-18	Incyte Corporation	Heteroaryl fluoroalkenes as dgk inhibitors
US20240294651A1 (en)	2023-01-30	2024-09-05	Kymab Limited	Antibodies
WO2024163477A1 (en)	2023-01-31	2024-08-08	University Of Rochester	Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024192033A1 (en)	2023-03-13	2024-09-19	Regeneron Pharmaceuticals, Inc.	Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2024196952A1 (en)	2023-03-20	2024-09-26	Bristol-Myers Squibb Company	Tumor subtype assessment for cancer therapy
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024200571A1 (en)	2023-03-28	2024-10-03	Institut National de la Santé et de la Recherche Médicale	Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024206357A1 (en)	2023-03-29	2024-10-03	Merck Sharp & Dohme Llc	Il4i1 inhibitors and methods of use
WO2024209072A1 (en)	2023-04-06	2024-10-10	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 for treating cancer
WO2024216028A1 (en)	2023-04-12	2024-10-17	Agenus Inc.	Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024213767A1 (en)	2023-04-14	2024-10-17	Institut National de la Santé et de la Recherche Médicale	Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
US20240390340A1 (en)	2023-04-18	2024-11-28	Incyte Corporation	Pyrrolidine kras inhibitors
WO2024223299A2 (en)	2023-04-26	2024-10-31	Isa Pharmaceuticals B.V.	Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2024228167A1 (en)	2023-05-03	2024-11-07	Iox Therapeutics Inc.	Inkt cell modulator liposomal compositions and methods of use
WO2024233926A1 (en)	2023-05-10	2024-11-14	Regeneron Pharmaceuticals, Inc.	Cd20-pd1 binding molecules and methods of use thereof
WO2024231384A1 (en)	2023-05-10	2024-11-14	Institut National de la Santé et de la Recherche Médicale	Compositions for treating senescence related disease
WO2024245951A1 (en)	2023-05-26	2024-12-05	Institut National de la Santé et de la Recherche Médicale	Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
WO2024254245A1 (en)	2023-06-09	2024-12-12	Incyte Corporation	Bicyclic amines as cdk2 inhibitors
WO2024256635A1 (en)	2023-06-15	2024-12-19	Institut National de la Santé et de la Recherche Médicale	Dpm1 inhibitor for treating cancer
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2024261239A1 (en)	2023-06-23	2024-12-26	Imcheck Therapeutics	Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025003193A1 (en)	2023-06-26	2025-01-02	Institut National de la Santé et de la Recherche Médicale	Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025006811A1 (en)	2023-06-27	2025-01-02	Lyell Immunopharma, Inc.	Methods for culturing immune cells
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025030044A1 (en)	2023-08-02	2025-02-06	Regeneron Pharmaceuticals, Inc.	Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
WO2025030041A1 (en)	2023-08-02	2025-02-06	Regeneron Pharmaceuticals, Inc.	Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6641809B1 (en)	1990-03-26	2003-11-04	Bristol-Myers Squibb Company	Method of regulating cellular processes mediated by B7 and CD28
CA2072249C (en) *	1991-06-28	2003-06-17	Saiko Hosokawa	Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
AU7405294A (en)	1993-07-26	1995-02-20	Dana-Farber Cancer Institute	B7-2: ctl a4/cd 28 counter receptor
CA2143491C (en)	1994-03-01	2011-02-22	Yasumasa Ishida	A novel peptide related to human programmed cell death and dna encoding it
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
NZ517955A (en)	1999-08-23	2004-03-26	Dana Farber Cancer Inst Inc	PD-1, a receptor for B7-4 for modulating the immune response
PL362804A1 (en)	1999-08-23	2004-11-02	Dana-Farber Cancer Institute	Novel b7-4 molecules and uses therefor
AU6422799A (en)	1999-10-08	2001-04-23	Toshihiko Matsuo	Oculomedin and glaucoma
WO2001027279A1 (en)	1999-10-12	2001-04-19	Cambridge Antibody Technology	Human anti-adipocyte monoclonal antibodies and their use
AR036993A1 (es) *	2001-04-02	2004-10-20	Wyeth Corp	Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
ATE524495T1 (de)	2001-07-31	2011-09-15	Ono Pharmaceutical Co	Pd-1-spezifische substanz
IL149820A0 (en) *	2002-05-23	2002-11-10	Curetech Ltd	Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003288675B2 (en)	2002-12-23	2010-07-22	Medimmune Limited	Antibodies against PD-1 and uses therefor

2003
- 2003-12-22 AU AU2003288675A patent/AU2003288675B2/en not_active Ceased
- 2003-12-22 AT AT03780521T patent/ATE514713T1/de not_active IP Right Cessation
- 2003-12-22 CN CN2010101700224A patent/CN101899114A/zh active Pending
- 2003-12-22 US US10/540,084 patent/US7521051B2/en not_active Expired - Fee Related
- 2003-12-22 JP JP2004561922A patent/JP4511943B2/ja not_active Expired - Fee Related
- 2003-12-22 US US10/741,481 patent/US7488802B2/en not_active Expired - Fee Related
- 2003-12-22 WO PCT/IB2003/006304 patent/WO2004056875A1/en active Application Filing
- 2003-12-22 MX MXPA05006828A patent/MXPA05006828A/es active IP Right Grant
- 2003-12-22 BR BR0316880-8A patent/BR0316880A/pt not_active IP Right Cessation
- 2003-12-22 ES ES03780521T patent/ES2367430T3/es not_active Expired - Lifetime
- 2003-12-22 CA CA2508660A patent/CA2508660C/en not_active Expired - Fee Related
- 2003-12-22 EP EP03780521A patent/EP1576014B1/en not_active Expired - Lifetime
- 2003-12-22 CN CN2003801099298A patent/CN1753912B/zh not_active Expired - Fee Related
2005
- 2005-06-14 IL IL169152A patent/IL169152A/en not_active IP Right Cessation
- 2005-07-12 NO NO20053389A patent/NO336442B1/no not_active IP Right Cessation
2006
- 2006-03-17 HK HK06103433.3A patent/HK1083510A1/xx not_active IP Right Cessation
2007
- 2007-08-17 US US11/893,989 patent/US20080311117A1/en not_active Abandoned
2009
- 2009-03-16 US US12/405,058 patent/US8088905B2/en not_active Expired - Fee Related
2010
- 2010-03-16 JP JP2010059987A patent/JP2010189395A/ja active Pending
- 2010-10-22 AU AU2010235966A patent/AU2010235966A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL169152A (en)	2010-11-30
AU2003288675B2 (en)	2010-07-22
NO20053389L (no)	2005-07-12
AU2010235966A1 (en)	2010-11-11
WO2004056875A1 (en)	2004-07-08
US20040213795A1 (en)	2004-10-28
US7488802B2 (en)	2009-02-10
EP1576014B1 (en)	2011-06-29
CN1753912B (zh)	2011-11-02
ATE514713T1 (de)	2011-07-15
CA2508660A1 (en)	2004-07-08
EP1576014A1 (en)	2005-09-21
AU2003288675A1 (en)	2004-07-14
CN1753912A (zh)	2006-03-29
JP4511943B2 (ja)	2010-07-28
CA2508660C (en)	2013-08-20
MXPA05006828A (es)	2005-09-08
US20100028330A1 (en)	2010-02-04
JP2010189395A (ja)	2010-09-02
NO20053389D0 (no)	2005-07-12
AU2003288675A8 (en)	2004-07-14
JP2006521783A (ja)	2006-09-28
US8088905B2 (en)	2012-01-03
CN101899114A (zh)	2010-12-01
ES2367430T3 (es)	2011-11-03
US7521051B2 (en)	2009-04-21
IL169152A0 (en)	2007-07-04
US20060210567A1 (en)	2006-09-21
US20080311117A1 (en)	2008-12-18
NO336442B1 (no)	2015-08-17
BR0316880A (pt)	2005-10-25

Publication	Publication Date	Title
HK1083510A1 (en)	2006-07-07	Antibodies against pd-1 and uses thereof
EP1603949B8 (en)	2010-03-10	Antibodies against human il-21 receptor and uses therefor
TW200801041A (en)	2008-01-01	Antibodies against human IL-22 and uses therefor
CR20200465A (es)	2020-11-17	Agentes anticuerpos anti-cd25
EP4248996A3 (en)	2023-11-08	Anti-trem2 antibodies and methods of use thereof
MX2019012364A (es)	2019-11-28	Proteinas de union a antigenos trem2 y usos de estas.
WO2020072821A3 (en)	2020-06-18	Il-12 heterodimeric fc-fusion proteins
NZ769634A (en)	2024-10-25	Anti-sirpa antibodies and methods of use thereof
WO2007100643A3 (en)	2008-03-06	Methods of using antibodies against human il-22
WO2020172631A3 (en)	2020-10-08	Untargeted and targeted il-10 fc-fusion proteins
EP1461081A4 (en)	2006-05-17	ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION
AU4455896A (en)	1996-08-14	A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses
MXPA04001566A (es)	2004-05-17	Un sistema para expresion y ensamblado de anticuerpos.
WO2021067863A3 (en)	2021-05-14	Targeted il-12 heterodimeric fc-fusion proteins
WO2006073443A3 (en)	2006-10-12	Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2020139926A3 (en)	2020-08-06	Anti-ctla4 antibodies and methods of use thereof
TW200500071A (en)	2005-01-01	Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
WO2020006374A3 (en)	2020-02-20	Anti-sirp-beta1 antibodies and methods of use thereof
WO2021127200A8 (en)	2022-07-14	Ilt3-binding agents and methods of use thereof
ATE358485T1 (de)	2007-04-15	Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
PH12020500664A1 (en)	2021-06-07	C3-binding agents and methods of use thereof
MY149448A (en)	2013-08-30	Interleukin-21 receptor binding proteins
DE60215649D1 (de)	2006-12-07	Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
MXPA03007413A (es)	2003-11-18	Composicion y metodo para tratar enfermedades inflamatorias.
WO2021024133A3 (en)	2021-03-25	Biopharmacuetical compositions and related methods

Legal Events

Date	Code	Title	Description
2017-07-21	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20161222